Chronic_Obstructive_Pulmonary_Disease

Complex MONDO:0005002 Pathograph 14 Show in embeddings browser Respiratory Disease Smoking-Related Disease

Chronic obstructive pulmonary disease is a progressive disorder of persistent, incompletely reversible airflow limitation caused by chronic inflammation of the airways and lung parenchyma, most often from long-term inhalation of cigarette smoke or other noxious particles. The inflammatory response drives a protease-antiprotease imbalance and oxidative stress that destroy alveolar walls (emphysema) and produce small-airway fibrosis and mucus hypersecretion (chronic bronchitis), reducing elastic recoil and increasing airflow resistance. The result is chronic dyspnea, cough, and sputum production with recurrent exacerbations, air trapping, and hyperinflation, and in advanced disease hypoxemia and cor pulmonale.

Ask OpenScientist

Ask a research question about Chronic_Obstructive_Pulmonary_Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

9
Pathophys.
11
Phenotypes
1
Gaps
14
Pathograph
7
Genes
11
Medical Actions
2
Subtypes
6
References
2
Deep Research
🏷

Classifications

Harrison's Chapter
RESPIRATORY
◆

Subtypes

2
Chronic Bronchitis
Inflammation of the bronchial tubes leading to increased mucus production and chronic cough.
Show evidence (3 references)
PMID:23204254 SUPPORT
"Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD)."
The article clearly states that Chronic Bronchitis (CB) is a subtype of COPD, characterized by inflammation of the bronchial tubes leading to increased mucus production and chronic cough.
PMID:27264777 SUPPORT
"Chronic obstructive pulmonary disease (COPD) is an umbrella term that covers many clinical subtypes with clearly different pulmonary and extra-pulmonary characteristics."
The article supports that COPD has multiple subtypes with differing characteristics, encompassing conditions like Chronic Bronchitis.
PMID:22753831 SUPPORT
"Chronic cough and sputum production: a clinical COPD phenotype?"
The article discusses the phenotype of COPD which includes chronic cough and sputum production, indicative of conditions like Chronic Bronchitis.
Emphysema
Damage to the alveoli resulting in shortness of breath and reduced surface area for gas exchange.
Show evidence (2 references)
PMID:33926668 SUPPORT
"Chronic obstructive pulmonary usually is subcategorized into 2 groups: chronic bronchitis and emphysema."
This reference reiterates the point that emphysema is a recognized subtype of COPD.
PMID:21178627 SUPPORT
"Latest studies further support the association of emphysema and COPD with coal dust exposure."
This confirms that emphysema is considered a subtype of COPD, further supporting the statement.
C

Comorbidities

Asthma <-> Chronic Obstructive Pulmonary Disease
Disease B UNKNOWN CANDIDATE
Chronic Obstructive Pulmonary Disease <-> Fibromyalgia
Disease A UNKNOWN CANDIDATE
?

Discussions and Knowledge Gaps

1
Does restoring NAD+-dependent SIRT1 deacetylase activity causally reduce neutrophilic airway inflammation and alveolar epithelial senescence in COPD, and can SIRT1 activators overcome their pharmacokinetic limitations and be paired with biomarker-guided patient stratification to translate this protection into therapy?
KNOWLEDGE GAP OPEN gap_copd_sirt1_senescence_neutrophilic_translation
Attached to
pathophysiology#Chronic Inflammation pathophysiology#Cellular Senescence
SIRT1 is reported to protect against COPD by inhibiting NF-kB and STAT3, activating Nrf2 and FOXO3, and suppressing TGF-beta/Smad, thereby reducing neutrophilic inflammation, mitigating alveolar epithelial senescence, and helping restore protease/antiprotease balance. These protective effects are mechanistically distinct from SIRT1's role in asthma, where it chiefly attenuates type 2 inflammation and mucus hypersecretion, so the disease context appears to determine which downstream program SIRT1 restrains. The COPD entry captures chronic neutrophilic inflammation and cellular senescence as separate nodes but does not resolve whether SIRT1 activity is causally required to limit each one, nor in which cell type (alveolar epithelium, neutrophil, macrophage) the protective signaling resides. Translation is further limited by the poor pharmacokinetics of current SIRT1 activators and by the absence of biomarkers to select responders. Resolving the cell-type-specific basis of these context-dependent effects and the pharmacokinetic and stratification barriers would convert SIRT1 from a broadly cytoprotective pathway into a stratified COPD therapeutic target.
Seeded from PMID:42181267 — Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy
⚙

Pathophysiology

9
Airflow Limitation
Obstruction of airflow due to inflammation, mucus build-up, and remodeling of the airways.
Epithelial Cell CL:0000066
inflammatory response GO:0006954 airway remodeling
bronchus UBERON:0002185 small airway
Downstream
Progressive Respiratory Impairment Chronic airway inflammation and remodeling lead to progressive airflow obstruction and respiratory decline.
Show evidence (3 references)
PMID:23204254 SUPPORT
"CB is caused by overproduction and hypersecretion of mucus by goblet cells, which leads to worsening airflow obstruction by luminal obstruction of small airways, epithelial remodeling, and alteration of airway surface tension predisposing to collapse"
This study describes how mucus build-up and epithelial remodeling lead to airflow obstruction in COPD.
PMID:36108172 PARTIAL
"Phenotypic alterations in the lung epithelium have been widely implicated in chronic obstructive pulmonary disease (COPD) pathogenesis, but the precise mechanisms orchestrating this persistent inflammatory process remain unknown."
This study notes the involvement of epithelial cells in COPD but states that mechanisms remain unknown, partially supporting the role of epithelial cells in airflow obstruction.
PMID:38625125 SUPPORT
"Chronic exposure to environmental hazards causes airway epithelial dysfunction, primarily impaired physical barriers, immune dysfunction, and repair or regeneration. Impairment of airway epithelial function subsequently leads to exaggerated airway inflammation and remodeling, the main features..."
This study supports the statement by highlighting the role of epithelial dysfunction, inflammation, and remodeling in COPD pathophysiology.
Chronic Inflammation
Persistent irritation from inhaled substances like cigarette smoke leads to airway and alveolar inflammation.
Neutrophil CL:0000775 Macrophage CL:0000235 T-lymphocyte CL:0000084
inflammatory response GO:0006954 neutrophil degranulation GO:0043312
bronchus UBERON:0002185 alveolus of lung UBERON:0002299
Show evidence (5 references)
PMID:17305517 SUPPORT
"Neutrophils and macrophages have been implicated in this process; they release proteolytic enzymes and generate oxidants, which cause tissue damage, as well as cytokines and chemokines, which can potentiate inflammation and trigger an immune response."
The literature describes the involvement of neutrophils, macrophages, and T-lymphocytes in the inflammatory process associated with COPD, supporting the notion of persistent irritation and chronic inflammation.
PMID:24507838 SUPPORT
"This inflammation is characterized by increased numbers of alveolar macrophages, neutrophils, and T lymphocytes, which are recruited from the circulation."
This article further substantiates the involvement of these cell types (neutrophils, macrophages, and T-lymphocytes) in the pathophysiology of COPD, linking them to chronic inflammation.
PMID:38035712 SUPPORT
"In this study, we found that neutrophilic phenotype (NP, 58.0%) was the most common airway inflammation phenotype in patients with COPD, followed by mixed granulocytic phenotype (MGP, 32.6%)."
The study indicates that neutrophils are predominant in COPD, supporting the statement about chronic inflammation.
+ 2 more references
Airway Remodeling
Structural changes in the airway due to chronic inflammation, including fibrosis and increased airway thickness.
Smooth Muscle Cell CL:0000192
extracellular matrix organization GO:0030198 fibrosis
bronchus UBERON:0002185 small airway
Show evidence (3 references)
PMID:20500603 SUPPORT
"Moreover, airway remodelling occurs not only in asthma but also in several pulmonary disorders such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and systemic sclerosis."
The statement aligns with the mentioned literature which notes airway remodeling as part of chronic obstructive pulmonary disease.
PMID:30257694 SUPPORT
"Multiple dysfunctions of ASM contribute to modulating airway responses to stimuli, remodeling, and fibrosis, as well as influence the compliance of lungs."
The statement is supported as this literature highlights the role of airway smooth muscle cells in airway remodeling and fibrosis in COPD.
PMID:15347849 SUPPORT
"Increases in airway smooth muscle mass occur in large airways of severe asthmatics and in small airways of patients with COPD."
The literature supports the statement by confirming the involvement of smooth muscle cells and structural changes in the airways in COPD.
Alveolar Destruction
Breakdown of alveolar walls, leading to reduced surface area for gas exchange and loss of lung elasticity.
Alveolar Macrophage CL:0000583
proteolysis GO:0006508 extracellular matrix organization GO:0030198
alveolus of lung UBERON:0002299 lung parenchyma UBERON:0008946
Show evidence (4 references)
PMID:11993785 PARTIAL
"In the lung parenchyma, emphysema defined as alveolar destruction and airspace enlargement is present."
While the reference supports alveolar destruction as part of COPD's pathophysiology, it does not mention alveolar macrophages specifically.
PMID:29433833 PARTIAL
"In inflammatory lung diseases such as chronic obstructive pulmonary disease (COPD), despite their increased numbers, macrophages demonstrate significantly reduced phagocytic capacity of bacteria and apoptotic cells."
The macrophages' role in the pathophysiology of COPD is discussed, focusing on their reduced phagocytic capacity rather than direct alveolar destruction.
PMID:32493486 PARTIAL
"External insults like smoke and pollution can disturb surfactant homeostasis and result in either surfactant insufficiency or accumulation. But disruption of surfactant homeostasis is also observed in many chronic adult diseases, including chronic obstructive pulmonary disease (COPD)."
The role of alveolar macrophages (responsible for the degradation of surfactant) in the development of COPD is mentioned, but no direct link to alveolar destruction.
+ 1 more reference
Oxidative Stress and Mitochondrial Dysfunction
Cigarette smoke and pollutants trigger mitochondrial ROS production, impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.
airway epithelial cell CL:0002368 Alveolar Macrophage CL:0000583
response to oxidative stress GO:0006979 mitochondrion organization GO:0007005 mitophagy GO:0000422
bronchus UBERON:0002185 alveolus of lung UBERON:0002299
Show evidence (1 reference)
PMID:42181267 SUPPORT Other
"Shared benefits include mitigation of oxidative stress, mitochondrial dysfunction, and extracellular matrix remodeling"
This review identifies mitigation of oxidative stress as a shared benefit of SIRT1 activation in obstructive airway disease, supporting SIRT1's role as a regulator of oxidative stress in COPD.
Mucus Hypersecretion
Upregulation of MUC5AC and MUC5B, goblet cell hyperplasia, and impaired mucociliary clearance contribute to mucus plugging.
goblet cell CL:0000160 club cell CL:0000158
mucus secretion GO:0070254 cilium movement GO:0003341
bronchus UBERON:0002185 small airway
NLRP3 Inflammasome Activation
Mitochondrial ROS and particulate exposures activate NLRP3 inflammasome, leading to caspase-1 activation and IL-1β/IL-18 release.
Macrophage CL:0000235 airway epithelial cell CL:0002368
inflammatory response GO:0006954
NLRP3 inflammasome complex GO:0072559
bronchus UBERON:0002185 alveolus of lung UBERON:0002299
Cellular Senescence
Senescent epithelial, fibroblast, and immune cells exhibit senescence-associated secretory phenotype (SASP), promoting chronic inflammation and remodeling.
airway epithelial cell CL:0002368 fibroblast CL:0000057
cellular senescence GO:0090398 inflammatory response GO:0006954
lung UBERON:0002048
SIRT1-Mediated NAD+ Signaling and Protective Deacetylation
SIRT1 (Sirtuin 1), an NAD+-dependent deacetylase, exerts protective effects in COPD by inhibiting pro-inflammatory signaling pathways (NF-κB, STAT3) while activating stress-response transcription factors (Nrf2, FOXO3) and suppressing pro-fibrotic TGF-β/Smad signaling. In COPD, SIRT1 reduces neutrophilic inflammation, mitigates alveolar senescence, and helps restore protease/antiprotease balance. SIRT1 also mitigates oxidative stress and mitochondrial dysfunction.
Neutrophil CL:0000775 Airway Epithelial Cell CL:0002368 Alveolar Macrophage CL:0000583
SIRT1 hgnc:14929 NFKB1 hgnc:7794 STAT3 hgnc:11364 NFE2L2 hgnc:7782 FOXO3 hgnc:3821 TGFB1 hgnc:11766
protein deacetylation GO:0006476 response to oxidative stress GO:0006979 transcriptional regulation GO:0006355 negative regulation of inflammatory response GO:0050728
Downstream
Chronic Inflammation SIRT1-mediated deacetylation inhibits NF-κB and STAT3 signaling, reducing neutrophilic recruitment and pro-inflammatory cytokine production.
Cellular Senescence SIRT1 suppresses senescence-associated secretory phenotype (SASP) and promotes cell viability in epithelial and immune cells.
Alveolar Destruction SIRT1 suppresses TGF-β/Smad pro-fibrotic signaling and restores protease/antiprotease balance through Nrf2-mediated antioxidant responses.
Oxidative Stress and Mitochondrial Dysfunction SIRT1 activation of Nrf2 and FOXO3 enhances antioxidant defenses and mitochondrial homeostasis, reducing ROS-driven inflammasome activation.
Show evidence (3 references)
PMID:42181267 SUPPORT Other
"SIRT1, an NAD+-dependent deacetylase, exerting protective effects by inhibiting NF-κB and STAT3, activating Nrf2 and FOXO3, and suppressing TGF-β/Smad."
This review identifies the key molecular mechanisms through which SIRT1 exerts protective effects in COPD by targeting multiple pro-inflammatory and pro-fibrotic pathways.
PMID:42181267 SUPPORT Other
"in COPD, it reduces neutrophilic inflammation, alveolar senescence, and protease/antiprotease imbalance."
This review explicitly describes SIRT1's protective effects specific to COPD pathophysiology, directly addressing three key pathological mechanisms.
PMID:42181267 SUPPORT Other
"Shared benefits include mitigation of oxidative stress, mitochondrial dysfunction, and extracellular matrix remodeling."
Describes SIRT1's shared protective mechanisms across multiple pathophysiological domains relevant to asthma and COPD.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Referential integrity issues (1):
  • Target 'Progressive Respiratory Impairment' (from 'Airflow Limitation') not found in named elements
Pathograph: causal mechanism network for Chronic_Obstructive_Pulmonary_Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Musculoskeletal 1
Barrel Chest OCCASIONAL Barrel-shaped chest HP:0001552
Due to hyperinflation of the lungs
Show evidence (3 references)
PMID:25159007 PARTIAL
"Lung hyperinflation is highly prevalent in patients with chronic obstructive pulmonary disease and occurs across the continuum of the disease."
The reference supports the association of lung hyperinflation with COPD but does not specifically mention 'Barrel Chest' or its frequency.
PMID:34972922 PARTIAL
"Attempts to connect the products of the analysis of the EBC with the clinical manifestations of COPD such as dyspnea are scarce."
The reference discusses the clinical manifestations of COPD but does not specifically mention 'Barrel Chest' or its frequency.
PMID:23204254 NO_EVIDENCE
"Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD)."
The reference discusses chronic bronchitis in COPD but does not mention 'Barrel Chest' or its frequency.
Respiratory 7
Dyspnea VERY_FREQUENT Dyspnea HP:0002094
Sequelae: Exercise Intolerance
Show evidence (3 references)
PMID:28277858 SUPPORT
"Indeed, it is an important symptom in chronic obstructive pulmonary disease (COPD), where it is associated with limited physical activity, increased anxiety and depression, decreased health-related quality of life (HRQoL), and reduced survival."
The literature supports that dyspnea is a common symptom in COPD and is frequently observed in patients, confirming its categorization as a respiratory phenotype with diagnostic importance.
PMID:35698999 SUPPORT
"Dyspnoea and pain are symptoms of chronic obstructive pulmonary disease (COPD)... The pooled prevalence of pain and dyspnoea was 44% (95% confidence interval (CI) 35%-52%) and 91% (95% CI 87%-94%) respectively."
This study highlights the high prevalence of dyspnea in patients with COPD, further supporting its status as a very frequent respiratory phenotype.
PMID:34972922 SUPPORT
"Up to date research has shown a positive correlation between the elevated levels of some markers of EBC such as H2O2 and 8-isoprostane and dyspnea, while others present ambiguous results"
The correlation between dyspnea and COPD is reinforced by the positive association found with certain markers in exhaled breath condensate.
Chronic Cough VERY_FREQUENT Chronic cough HP:0034315
Often productive of mucus
Show evidence (2 references)
PMID:29881269 SUPPORT
"Compared with patients without chronic cough, those with chronic cough exhibited a lower forced expiratory volume in 1 second (% predicted) and diffusing capacity of the lungs for carbon monoxide (% predicted), more frequent AECOPD, more severe dyspnea, and worse QoL."
The study identifies chronic cough as a common and significant phenotype in COPD patients, indicating its very frequent occurrence and diagnostic importance.
PMID:31740261 SUPPORT
"COPD is now widely accepted as a heterogeneous condition with multiple phenotypes and endotypes. This review will discuss the old and new concepts for the different types of COPD phenotypes."
The statement mentions the heterogeneity of COPD with multiple phenotypes, which could include phenotypes like chronic cough.
Sputum Production VERY_FREQUENT Increased sputum production HP:0033709
Mucus is often difficult to expectorate
Show evidence (2 references)
PMID:22753831 SUPPORT
"Chronic cough and sputum production: a clinical COPD phenotype?"
The title of the article itself suggests that sputum production is recognized as a phenotype of COPD.
PMID:23204254 SUPPORT
"Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD)."
Chronic bronchitis, which involves overproduction and hypersecretion of mucus, is described as a common phenomenon in COPD, indicating sputum production is a frequent COPD phenotype.
Wheezing FREQUENT Wheezing HP:0030828
Due to airflow obstruction
Show evidence (3 references)
PMID:33302722 SUPPORT
"The clinical symptoms of this disease include progressive dyspnea, cough, expectoration, and wheezing, among others."
The abstract mentions wheezing as one of the clinical symptoms of Chronic Obstructive Pulmonary Disease (COPD).
PMID:11963614 SUPPORT
"Remember, all that wheezes is not asthma; therefore, providers in this case had to determine if the patient was suffering something such as anaphylaxis, asthma, bronchitis, pneumonia or even congestive heart failure (CHF)."
The abstract indicates that wheezing can be a symptom of various conditions, including COPD-related bronchospasm.
PMID:2404712 SUPPORT
"Increased airways reactivity is present in 15 to 70 percent of patients with chronic airflow obstruction."
The abstract discusses increased airway reactivity, which is related to wheezing, in patients with chronic airflow obstruction, including COPD.
Respiratory Failure OCCASIONAL Respiratory failure HP:0002878
Sequelae: Hypoxemia Hypercapnia
Show evidence (2 references)
PMID:14621114 REFUTE
"Respiratory failure is still an important complication of chronic obstructive pulmonary disease (COPD) and hospitalisation with an acute episode being a poor prognostic marker."
The reference indicates that respiratory failure is an important and common complication of COPD, not an occasional one.
PMID:38692758 REFUTE
"Hypoventilation is a complication that is not uncommon in chronic obstructive pulmonary disease and calls for both medical treatment of the underlying disease and, frequently, noninvasive ventilation either during exacerbations requiring hospitalization or in a chronic state in the patient at home."
The reference suggests that hypoventilation, which can lead to respiratory failure, is not uncommon in COPD.
Hypoxemia FREQUENT Hypoxemia HP:0012418
Hypercapnia FREQUENT Hypercapnia HP:0012416
Constitutional 2
Fatigue FREQUENT Fatigue HP:0012378
Show evidence (3 references)
PMID:33998496 SUPPORT
"Fatigue: A neglected symptom of COPD."
The title itself indicates that fatigue is a recognized symptom of COPD.
PMID:31729154 SUPPORT
"Fatigue is an important yet ignored symptom of chronic obstructive pulmonary disease (COPD)."
This reference acknowledges fatigue as an important symptom of COPD, supporting its frequent occurrence.
PMID:24874124 SUPPORT
"Symptoms in COPD do not solely arise from the degree of airflow obstruction as exercise limitation is compounded by the specific secondary manifestations of the disease including skeletal muscle impairment, osteoporosis, mood disturbance, anemia, and hormonal imbalance."
While this reference does not mention fatigue explicitly, it discusses systemic manifestations of COPD, implying the systemic nature of the disease.
Exercise Intolerance FREQUENT Exercise intolerance HP:0003546
Growth 1
Weight Loss OCCASIONAL Weight loss HP:0001824
More common in advanced disease
Show evidence (3 references)
PMID:12406664 SUPPORT
"Weight loss occurs frequently in patients with chronic obstructive pulmonary disease (COPD)."
The literature states that weight loss is a common phenomenon in COPD patients, which supports the statement that weight loss is a systemic issue in COPD, more common in advanced disease.
PMID:18415812 SUPPORT
"These include unintentional weight loss, skeletal muscle dysfunction, an increased risk of cardiovascular disease, osteoporosis, and depression, among others."
This reference mentions unintentional weight loss as one of the systemic effects of COPD, supporting the statement.
PMID:36922031 SUPPORT
"COPD patients with psychological (high anxiety and depression) and cachectic (underweight and osteoporotic) comorbidity have higher mortality and exacerbate more."
The mention of cachexia (underweight) as a comorbidity in COPD patients aligns with the statement about weight loss being more common in advanced disease.
🧬

Genetic Associations

7
SERPINA1 (Alpha-1 antitrypsin deficiency is the most common genetic cause of COPD.)
Show evidence (3 references)
PMID:32800189 SUPPORT
"Alpha-1 antitrypsin deficiency (AATD) was the first genetic risk factor for chronic obstructive pulmonary disease (COPD) described."
The abstract clearly mentions that AATD is a genetic risk factor for COPD, supporting the statement.
PMID:35104244 SUPPORT
"Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause and risk factor for chronic obstructive pulmonary disease."
The text directly supports the statement by identifying AATD as a common genetic cause and risk factor for COPD.
PMID:36630963 SUPPORT
"Genetic variation in alpha-1 antitrypsin (AAT) causes AAT deficiency (AATD) through liver aggregation-associated gain-of-toxic pathology and/or insufficient AAT activity in the lung manifesting as chronic obstructive pulmonary disease (COPD)."
The abstract highlights that genetic variation in AAT leading to AATD manifests as COPD, thus supporting the statement.
MMP12 (Matrix metalloproteinase-12 contributes to emphysema development.)
NLRP3 (Inflammasome activation contributes to chronic inflammation.)
TNF (Tumor necrosis factor mediates systemic and airway inflammation.)
IL1B (Interleukin-1 beta drives inflammatory signaling.)
IL6 (Interleukin-6 contributes to systemic inflammation.)
NFE2L2 (Nrf2 transcription factor regulates antioxidant defense.)
💊

Medical Actions

11
Smoking Cessation
Action: behavioral counseling MAXO:0000077
Stopping smoking to slow disease progression and improve outcomes.
Show evidence (4 references)
PMID:25496790 SUPPORT
"Stopping smoking reduces the risk of developing COPD and is an essential treatment for this inflammatory disease. Smoking cessation decreases the prevalence of respiratory symptoms, number of hospitalizations, and decline in FEV1, as well as exacerbation frequency and overall mortality."
The reference clearly states that smoking cessation is essential in reducing various harmful outcomes related to COPD.
PMID:19811377 SUPPORT
"Smoking cessation and lung volume reduction surgery would both qualify as disease-modifying interventions."
The reference identifies smoking cessation as a disease-modifying intervention, which indicates its importance in slowing disease progression and thus improving outcomes.
PMID:11935838 SUPPORT
"The most important intervention is smoking cessation."
The reference emphasizes that smoking cessation is the most important intervention to minimize the impact of COPD.
+ 1 more reference
Bronchodilators
Action: bronchodilator therapy MAXO:0000316
Medications that relax muscles of the airways to improve airflow (e.g., beta-agonists, anticholinergics).
Show evidence (3 references)
PMID:29794201 SUPPORT
"Bronchodilator therapy can often decrease symptoms of air-flow obstruction by relaxing airway smooth muscle (bronchodilation), decreasing dyspnea, and improving quality of life."
The reference discusses how bronchodilator therapy relaxes airway smooth muscle, which improves airflow in obstructive lung diseases like COPD.
PMID:27576232 SUPPORT
"Long-acting beta2-agonists and long-acting muscarinic antagonists are first-line treatments for patients with persistently symptomatic COPD with an FEV1 of 80% or less of predicted."
This reference identifies bronchodilators, specifically long-acting beta2-agonists and muscarinic antagonists, as key treatments for COPD by improving airflow.
PMID:28757318 SUPPORT
"Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease."
This reference confirms that bronchodilators, such as long-acting beta2 agonists and long-acting muscarinic antagonists, are used to manage COPD symptoms by improving pulmonary function.
Inhaled Corticosteroids
Action: respiratory tract agent therapy MAXO:0000312
Reduce airway inflammation and frequency of exacerbations.
Show evidence (4 references)
PMID:20102305 PARTIAL
"Short-term treatment with ICS improves lung function and quality of life; in addition, several studies with longer follow-up have shown less decline over time in quality of life, and fewer exacerbations. By contrast, long-term studies have been unable to show substantial improvement in the..."
While ICS do help reduce the frequency of exacerbations and improve quality of life, the evidence on their effectiveness in reducing airway inflammation specifically is more nuanced.
PMID:37348121 PARTIAL
"Current pharmacologic strategies, including first- and second-line therapies such as long-acting β2-agonists, long-acting muscarinic antagonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, and macrolides, provide relief to patients with COPD"
ICS are included in the treatment strategies, and while they help mitigate exacerbations, the snippet suggests that not all patients experience reduced airway inflammation.
PMID:29938633 SUPPORT
"The major alteration has been in the section concerning treatment with inhalation medication - now aiming at an easy stepwise up-titration of long-acting medicine as well as a guide of how to down-titrate inhaled corticosteroids."
The guideline update underscores the role of ICS in managing stable COPD, highlighting their long-term use for reducing symptoms and managing exacerbations.
+ 1 more reference
Phosphodiesterase-4 Inhibitors
Action: Pharmacotherapy NCIT:C15986
Reduce inflammation and relax airways.
Show evidence (4 references)
PMID:15699784 SUPPORT
"Some of the selective PDE4 inhibitors have demonstrated in vitro and in vivo anti-inflammatory activity on cells commonly linked to airway inflammation in COPD, such as neutrophils."
The reference indicates that selective phosphodiesterase 4 inhibitors show anti-inflammatory activity, supporting the statement about reducing inflammation.
PMID:20649375 SUPPORT
"Roflumilast targets inflammatory processes in COPD, with beneficial effects on tobacco-induced lung inflammation, lung fibrosis and remodeling, mucociliary malfunction and oxidative stress."
Roflumilast, a PDE4 inhibitor, targets inflammatory processes, thus supporting the statement.
PMID:34731461 SUPPORT
"The orally administered PDE4 inhibitor roflumilast reduces exacerbation rates in the subgroup of chronic obstructive pulmonary disease patients with a history of exacerbations and the presence of chronic bronchitis, but can cause PDE4 related adverse effects due to systemic exposure."
This reference confirms the anti-inflammatory effect of PDE4 inhibitors which aligns with the statement.
+ 1 more reference
Oxygen Therapy
Action: Oxygen Therapy NCIT:C94624
Long-term oxygen use for patients with severe chronic hypoxemia.
Show evidence (3 references)
PMID:24461631 SUPPORT
"This therapeutic intervention has been shown to increase survival in patients with chronic obstructive pulmonary disease (COPD) and respiratory failure."
The literature supports that long-term oxygen therapy (LTOT) is used to treat patients with COPD who have severe chronic hypoxemia.
PMID:37353334 SUPPORT
"Long-term oxygen therapy (LTOT) is a mainstay treatment for patients with severe resting hypoxemia secondary to chronic respiratory conditions including COPD."
This reference specifically mentions LTOT as a primary treatment for patients with severe chronic hypoxemia due to COPD.
PMID:19462352 SUPPORT
"Only smoking cessation and long term oxygen therapy (LTOT) improve survival in COPD."
This study confirms that LTOT is a treatment that improves survival in patients with severe COPD and chronic hypoxemia.
Pulmonary Rehabilitation
Action: physical therapy MAXO:0000011
Exercise training, education, and support to improve quality of life and physical conditioning.
Show evidence (5 references)
PMID:29526182 SUPPORT
"PR is an effective and cost-effective therapeutic intervention that improves physical performance ability, shortness of breath, and the quality of life in patients with COPD."
The reference indicates that pulmonary rehabilitation (PR) improves physical performance, shortness of breath, and quality of life in COPD patients, aligning with the statement's description of treatments including exercise training, education, and support.
PMID:34338012 SUPPORT
"Exercise improves the physiological and psychological condition of people with chronic obstructive pulmonary disease and should be encouraged, with referral to a pulmonary rehabilitation service if available."
This reference supports the statement's claim by emphasizing the importance of exercise and recommending pulmonary rehabilitation to improve the quality of life and physical conditioning in COPD patients.
PMID:34955635 SUPPORT
"The combination of drug therapy with non-drug therapy such as pulmonary rehabilitation training has demonstrated a great potential in reducing the occurrence of complications and delaying the progression of COPD."
This reference supports the statement by highlighting the benefits of pulmonary rehabilitation training, specifically its potential to improve quality of life and physical conditioning in COPD patients.
+ 2 more references
Lung Volume Reduction Surgery
Action: surgical procedure MAXO:0000004
Surgical removal of damaged lung tissue for severe emphysema.
Show evidence (3 references)
PMID:22189668 SUPPORT
"Surgical approaches include lung transplantation and lung volume reduction and the latter has been shown to improve exercise tolerance, quality of life, and survival in highly selected patients with advanced emphysema."
The literature supports the use of lung volume reduction surgery as a treatment for severe emphysema in chronic obstructive pulmonary disease (COPD) patients.
PMID:33926668 SUPPORT
"As symptoms and lung function decline, treatment modalities, such as lung volume reduction surgery, have been used in individuals with chronic obstructive pulmonary disease and upper lobe predominant emphysema."
The literature indicates that lung volume reduction surgery is a treatment used for severe emphysema, a condition associated with COPD.
PMID:31145187 SUPPORT
"Mortality benefits to therapy have been demonstrated in only 2 therapeutic interventions to date: long-term use of daily supplemental oxygen and surgical lung volume reduction (LVRS) for upper-lobe-predominant disease in patients with a low baseline exercise capacity."
The statement is supported as the literature suggests that lung volume reduction surgery is an established treatment for upper-lobe-predominant, severe emphysema in COPD patients.
Lung Transplantation
Action: organ transplantation MAXO:0010039
Considered in end-stage COPD with severe impairment.
Show evidence (4 references)
PMID:17240617 SUPPORT
"Lung transplantation is a surgical option for patients who fail optimization of medical treatment for the severe symptoms that result from COPD."
This reference states that lung transplantation is a considered treatment option for patients with severe symptoms resulting from COPD.
PMID:31375190 SUPPORT
"End-stage congestive heart failure, chronic obstructive pulmonary disease...palliative principles can guide decision making and symptom management in these disease states."
The reference focuses on end-stage COPD and mentions lung transplantation as a consideration in managing the conditions of patients.
PMID:36050206 SUPPORT
"The International Thoracic Organ Transplant Registry...focus on lung transplant recipients with chronic obstructive pulmonary disease."
This source concentrates on lung transplantation for patients with COPD, in line with the statement's context of it being a treatment for end-stage COPD.
+ 1 more reference
Mucolytic Therapy
Action: Pharmacotherapy NCIT:C15986
N-acetylcysteine and other mucolytics reduce mucus viscosity and may improve mucociliary clearance.
Macrolide Antibiotics
Action: antibiotic therapy Ontology label: Antibiotic Therapy NCIT:C15620
Long-term macrolide therapy reduces exacerbation frequency but raises antimicrobial resistance concerns.
Biologic Therapies
Action: biologic therapy Ontology label: Immunotherapy NCIT:C15262
Precision biologics targeting Type 2 inflammation in eosinophilic COPD subsets.
🌍

Environmental Factors

3
Smoking
Tobacco smoking exposure ECTO:6000029
Primary risk factor for development and progression.
Show evidence (5 references)
PMID:30810540 SUPPORT
"Although cigarette smoking is the major risk factor, only 10-20% of smokers develop COPD."
This clearly identifies smoking as a major risk factor for COPD development.
PMID:31759959 SUPPORT
"The observation that COPD is an independent risk factor for cardiovascular disease (CVDs) comes from comparisons between smokers with COPD and smokers without COPD."
This snippet highlights the relationship between smoking, COPD, and other health issues, indirectly supporting smoking as a risk factor for COPD.
PMID:28933915 SUPPORT
"The epithelial lining of the airway forms the first barrier against environmental insults, such as inhaled cigarette smoke, which is the primary risk factor for the development of chronic obstructive pulmonary disease (COPD)."
Directly states that cigarette smoke is the primary risk factor for COPD development.
+ 2 more references
Air Pollution
Air pollution exposure ECTO:8000036
Exposure to pollutants can exacerbate symptoms.
Show evidence (5 references)
PMID:33542053 SUPPORT
"Our findings suggest that, when considering total personal exposure to air pollutants, mainly the gaseous pollutants affect COPD patients' health."
This study found that exposure to various air pollutants adversely affects the health of COPD patients, supporting the idea that air pollution exacerbates COPD symptoms.
PMID:25673984 SUPPORT
"The major pathogenic factors causing disease include infection and inflammation, protease and antiprotease imbalance, and oxidative stress overwhelming antioxidant defenses."
This reference discusses environmental factors, including pollutants, that contribute to oxidative stress and inflammation in COPD, thus supporting the statement.
PMID:37068517 SUPPORT
"Harmful inhaled workplace exposures can contribute to the development of chronic obstructive pulmonary disease (COPD)."
This statement supports the environmental influence on COPD, including air pollutants, as a risk factor.
+ 2 more references
Occupational Dust and Chemicals
Occupational dust exposure ECTO:7000001
Long-term exposure increases risk.
Show evidence (5 references)
PMID:11964759 SUPPORT
"occupational exposure to dusts, chemicals and gases will be considered an established, or supported by good evidence, risk factor for chronic obstructive pulmonary disease"
The abstract confirms that occupational exposure to dusts, chemicals, and gases is a well-supported risk factor for chronic obstructive pulmonary disease.
PMID:20535848 SUPPORT
"Lung function loss associated with occupational dust exposure in metal smelting"
This study provides evidence of lung function loss due to occupational dust exposure, supporting the assertion that long-term exposure to such environmental factors increases the risk of chronic obstructive pulmonary disease.
PMID:23361196 SUPPORT
"Recent studies have recognized the contribution of workplace exposures to chronic lung diseases, in particular chronic obstructive pulmonary disease (COPD)"
The abstract discusses the recognized contribution of workplace exposures, including textile dust, to chronic obstructive pulmonary disease.
+ 2 more references
🔬

Biochemical Markers

3
Arterial Blood Gases (Altered)
Show evidence (4 references)
PMID:21812941 PARTIAL
"The aim of this study was to identify predictors of hypoxemia, hypercapnia and increased alveolar-arterial oxygen difference in COPD patients."
The study confirms that COPD patients may show hypoxemia and hypercapnia, but it focuses on the predictors rather than just the presence of these conditions.
PMID:34756790 SUPPORT
"Respiratory acidosis with hypoxia, hypercapnia, a compensatory metabolic response, and mild hyperfibrinolysis were probably related to the combined effect of nitrogen compounds and the inhaled toxic products of detonation."
The study discusses the occurrence of hypoxia and hypercapnia in specific exposure situations, including COPD contexts.
PMID:25119324 SUPPORT
"The prevalence of this sampling method has grown among health professionals, coupled with a growing demand for domiciliary oxygen therapy in the UK, in particular for those who have chronic obstructive pulmonary disease (COPD)."
While this does not directly confirm hypoxemia and hypercapnia, it suggests the necessity of oxygen therapy for COPD patients, implying altered arterial blood gases.
+ 1 more reference
C-Reactive Protein (CRP) (Elevated)
Context: General inflammation and exacerbations.
Show evidence (5 references)
PMID:23206444 SUPPORT
"Patients with COPD had higher serum CRP concentrations than healthy controls (WMD 4.72 mg/l, 95% CI 2.98, 6.47)."
This meta-analysis suggests that patients with stable COPD had higher serum CRP concentrations than healthy controls, indicating elevated CRP in general inflammation related to COPD.
PMID:24313775 SUPPORT
"These biomarkers include C-reactive protein, procalcitonin, and peripheral blood eosinophil count, which are readily available."
The study identifies CRP as an important biomarker in COPD exacerbations, indicating its elevation in such contexts.
PMID:24102428 SUPPORT
"Serum CRP levels were also significantly higher on D1 compared to D7 (p < 0.001)."
The findings that CRP levels are elevated at the onset of COPD exacerbations support the statement.
+ 2 more references
Forced Expiratory Volume in 1 Second (FEV1) (Reduced, with a low post-bronchodilator FEV1/FVC ratio confirming persistent airflow limitation; partially reversible or more slowly declining with bronchodilator and anti-inflammatory therapy.)
Context: Spirometric pulmonary function measure (percent of predicted FEV1, together with the FEV1/FVC ratio) used to diagnose COPD, grade severity of airflow limitation, monitor disease progression, and assess pharmacodynamic response to bronchodilator and anti-inflammatory therapy. FEV1 is recognized by the FDA as a validated surrogate endpoint supporting traditional approval of COPD drugs.
Pathograph Readouts
Pharmacodynamic Marker Of Airflow Limitation Negative Pharmacodynamic
Higher or less-declining percent-predicted FEV1 indicates reduced airflow limitation; treatment-induced improvement in FEV1 reports the pharmacodynamic response to bronchodilator and anti-inflammatory therapy and underpins the FDA surrogate-endpoint basis for traditional approval of COPD drugs.
Forced expiratory volume in 1 second (FEV1)
Traditional Validated Surrogate Endpoint
Patients with COPD
Show evidence (2 references)
PMID:19716960 SUPPORT Human Clinical
"Primary endpoints were change in prebronchodilator forced expiratory volume in 1 s (FEV(1)) and the rate of exacerbations that were moderate (glucocorticosteroid-treated) or severe."
The pivotal placebo-controlled trials of the phosphodiesterase-4 inhibitor roflumilast used change in prebronchodilator FEV1 as a primary endpoint, establishing FEV1 as a regulatory efficacy readout for COPD drug approval.
PMID:19716960 SUPPORT Human Clinical
"In a pooled analysis, prebronchodilator FEV(1) increased by 48 mL with roflumilast compared with placebo (p<0.0001)."
FEV1 improved measurably with anti-inflammatory therapy versus placebo, confirming FEV1 as a treatment-responsive pharmacodynamic marker of airflow limitation in COPD.
Show evidence (1 reference)
PMID:18836213 SUPPORT Human Clinical
"The patients were at least 40 years of age, with a forced expiratory volume in 1 second (FEV(1)) of 70% or less after bronchodilation and a ratio of FEV(1) to forced vital capacity (FVC) of 70% or less."
Reduced FEV1 and a low FEV1/FVC ratio are the spirometric criteria used to define and grade airflow limitation in COPD, supporting FEV1 as the core monitoring and severity biomarker.
{ }

Source YAML

click to show 
name: Chronic_Obstructive_Pulmonary_Disease
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-04-22T20:53:03Z'
description: >-
  Chronic obstructive pulmonary disease is a progressive disorder of persistent,
  incompletely reversible airflow limitation caused by chronic inflammation of
  the airways and lung parenchyma, most often from long-term inhalation of
  cigarette smoke or other noxious particles. The inflammatory response drives a
  protease-antiprotease imbalance and oxidative stress that destroy alveolar
  walls (emphysema) and produce small-airway fibrosis and mucus hypersecretion
  (chronic bronchitis), reducing elastic recoil and increasing airflow
  resistance. The result is chronic dyspnea, cough, and sputum production with
  recurrent exacerbations, air trapping, and hyperinflation, and in advanced
  disease hypoxemia and cor pulmonale.
category: Complex
parents:
- Respiratory Disease
- Smoking-Related Disease
has_subtypes:
- name: Chronic Bronchitis
  description: Inflammation of the bronchial tubes leading to increased mucus production and chronic cough.
  evidence:
  - reference: PMID:23204254
    reference_title: "Chronic bronchitis and chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD).
    explanation: The article clearly states that Chronic Bronchitis (CB) is a subtype of COPD, characterized by inflammation of the bronchial tubes leading to increased mucus production and chronic cough.
  - reference: PMID:27264777
    reference_title: "Management of chronic obstructive pulmonary disease beyond the lungs."
    supports: SUPPORT
    snippet: Chronic obstructive pulmonary disease (COPD) is an umbrella term that covers many clinical subtypes with clearly different pulmonary and extra-pulmonary characteristics.
    explanation: The article supports that COPD has multiple subtypes with differing characteristics, encompassing conditions like Chronic Bronchitis.
  - reference: PMID:22753831
    reference_title: "Chronic cough and sputum production: a clinical COPD phenotype?"
    supports: SUPPORT
    snippet: 'Chronic cough and sputum production: a clinical COPD phenotype?'
    explanation: The article discusses the phenotype of COPD which includes chronic cough and sputum production, indicative of conditions like Chronic Bronchitis.
- name: Emphysema
  description: Damage to the alveoli resulting in shortness of breath and reduced surface area for gas exchange.
  evidence:
  - reference: PMID:33926668
    reference_title: "Alpha(1)-antitrypsin Disease, Treatment and Role for Lung Volume Reduction Surgery."
    supports: SUPPORT
    snippet: 'Chronic obstructive pulmonary usually is subcategorized into 2 groups: chronic bronchitis and emphysema.'
    explanation: This reference reiterates the point that emphysema is a recognized subtype of COPD.
  - reference: PMID:21178627
    reference_title: "Emphysema and chronic obstructive pulmonary disease in coal miners."
    supports: SUPPORT
    snippet: Latest studies further support the association of emphysema and COPD with coal dust exposure.
    explanation: This confirms that emphysema is considered a subtype of COPD, further supporting the statement.
prevalence:
- population: Global
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 11700.0
  percentage: 11.7
  evidence:
  - reference: PMID:35261410
    reference_title: "Prevalence of chronic obstructive pulmonary disease and chronic bronchitis in eight countries: a systematic review and meta-analysis."
    supports: NO_EVIDENCE
    snippet: 'The estimated pooled prevalence of COPD was 11.1% (95% confidence interval, CI: 7.4-14.8%), using the Global Initiative for Chronic Obstructive Lung Disease fixed criteria and 8.0% (95% CI: 5.6-10.4%) using the lower limit of normal criteria.'
    explanation: The study provides prevalence data for specific regions (e.g., South Asia) but does not mention a global prevalence rate of 11.7%.
  - reference: PMID:37461046
    reference_title: "Global incidence, prevalence and disease burden of silicosis: 30 years' overview and forecasted trends."
    supports: NO_EVIDENCE
    snippet: Though disease burden of silicosis has been on a decline in general from 1990 to 2019, which shows a promising prospect but cannot be ignored.
    explanation: This study focuses on the global incidence, prevalence, and disease burden of silicosis, not COPD.
progression:
- phase: Onset
  notes: Typically begins in individuals over the age of 40.
  evidence:
  - reference: PMID:26154786
    reference_title: "Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease."
    supports: PARTIAL
    snippet: Among 657 persons who had an FEV1 of less than 80% of the predicted value before 40 years of age, 174 (26%) had COPD after 22 years of observation, whereas among 2207 persons who had a baseline FEV1 of at least 80% of the predicted value before 40 years of age, 158 (7%) had COPD after 22 years of observation.
    explanation: The literature suggests that COPD can develop in individuals with low FEV1 before the age of 40. While this supports the idea that COPD typically begins in individuals over 40, it also indicates that it can start earlier in some cases.
  - reference: PMID:19934351
    reference_title: "The aging lung and chronic obstructive pulmonary disease: similarity and difference."
    supports: SUPPORT
    snippet: There is growing evidence of higher prevalence of chronic obstructive pulmonary disease (COPD) in the elderly. Age-associated changes in the structure and function of the lung may increase a pathogenetic susceptibility to COPD.
    explanation: This reference supports the statement that COPD typically begins in individuals over the age of 40, particularly due to age-associated changes in lung structure and function.
pathophysiology:
- name: Airflow Limitation
  description: Obstruction of airflow due to inflammation, mucus build-up, and remodeling of the airways.
  cell_types:
  - preferred_term: Epithelial Cell
    term:
      id: CL:0000066
      label: epithelial cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: airway remodeling
    description: Structural changes in airway architecture
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: small airway
    description: Terminal and respiratory bronchioles
  downstream:
  - target: Progressive Respiratory Impairment
    description: Chronic airway inflammation and remodeling lead to progressive airflow obstruction and respiratory decline.
    evidence:
    - reference: PMID:39046133
      reference_title: "Small airways disease in chronic obstructive pulmonary disease."
      supports: SUPPORT
      snippet: Chronic exposure to smoking and noxious particles or gases induces inflammation and remodeling, leading to airway obstruction and SAD, eventually resulting in complete airway loss.
      explanation: This 2024 review establishes that chronic inflammation and remodeling cause irreversible airflow limitation and progressive respiratory decline in COPD.
  evidence:
  - reference: PMID:23204254
    reference_title: "Chronic bronchitis and chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: CB is caused by overproduction and hypersecretion of mucus by goblet cells, which leads to worsening airflow obstruction by luminal obstruction of small airways, epithelial remodeling, and alteration of airway surface tension predisposing to collapse
    explanation: This study describes how mucus build-up and epithelial remodeling lead to airflow obstruction in COPD.
  - reference: PMID:36108172
    reference_title: "Anomalous Epithelial Variations and Ectopic Inflammatory Response in Chronic Obstructive Pulmonary Disease."
    supports: PARTIAL
    snippet: Phenotypic alterations in the lung epithelium have been widely implicated in chronic obstructive pulmonary disease (COPD) pathogenesis, but the precise mechanisms orchestrating this persistent inflammatory process remain unknown.
    explanation: This study notes the involvement of epithelial cells in COPD but states that mechanisms remain unknown, partially supporting the role of epithelial cells in airflow obstruction.
  - reference: PMID:38625125
    reference_title: "Revisiting airway epithelial dysfunction and mechanisms in chronic obstructive pulmonary disease: the role of mitochondrial damage."
    supports: SUPPORT
    snippet: Chronic exposure to environmental hazards causes airway epithelial dysfunction, primarily impaired physical barriers, immune dysfunction, and repair or regeneration. Impairment of airway epithelial function subsequently leads to exaggerated airway inflammation and remodeling, the main features of chronic obstructive pulmonary disease (COPD).
    explanation: This study supports the statement by highlighting the role of epithelial dysfunction, inflammation, and remodeling in COPD pathophysiology.
- name: Chronic Inflammation
  description: Persistent irritation from inhaled substances like cigarette smoke leads to airway and alveolar inflammation.
  cell_types:
  - preferred_term: Neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: T-lymphocyte
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: neutrophil degranulation
    term:
      id: GO:0043312
      label: neutrophil degranulation
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  evidence:
  - reference: PMID:17305517
    reference_title: "Inflammatory cells and chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Neutrophils and macrophages have been implicated in this process; they release proteolytic enzymes and generate oxidants, which cause tissue damage, as well as cytokines and chemokines, which can potentiate inflammation and trigger an immune response.
    explanation: The literature describes the involvement of neutrophils, macrophages, and T-lymphocytes in the inflammatory process associated with COPD, supporting the notion of persistent irritation and chronic inflammation.
  - reference: PMID:24507838
    reference_title: "Cellular and molecular mechanisms of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: This inflammation is characterized by increased numbers of alveolar macrophages, neutrophils, and T lymphocytes, which are recruited from the circulation.
    explanation: This article further substantiates the involvement of these cell types (neutrophils, macrophages, and T-lymphocytes) in the pathophysiology of COPD, linking them to chronic inflammation.
  - reference: PMID:38035712
    reference_title: "Characteristics of inflammatory phenotypes in patients with chronic obstructive pulmonary disease: a cross-sectional study."
    supports: SUPPORT
    snippet: In this study, we found that neutrophilic phenotype (NP, 58.0%) was the most common airway inflammation phenotype in patients with COPD, followed by mixed granulocytic phenotype (MGP, 32.6%).
    explanation: The study indicates that neutrophils are predominant in COPD, supporting the statement about chronic inflammation.
  - reference: PMID:38891820
    reference_title: "Macrophage Polarization and Functions in Pathogenesis of Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: Recent multiomics-based evidence suggests that the plasticity of alveolar macrophages contributes to the onset and progression of COPD through the coordinated modulation of numerous transcription factors.
    explanation: The article highlights the role of macrophages in the pathogenesis and progression of COPD, thus supporting the statement.
  - reference: PMID:11993785
    reference_title: "Pathology and pathophysiology of chronic obstructive pulmonary disease."
    supports: PARTIAL
    snippet: The characteristic changes in the central airways include inflammatory cellular infiltration into the airway wall and mucous gland enlargement.
    explanation: This reference provides a broader overview of the pathological changes in COPD, mentioning inflammatory cells but not specifically detailing the involvement of neutrophils, macrophages, and T-lymphocytes.
- name: Airway Remodeling
  description: Structural changes in the airway due to chronic inflammation, including fibrosis and increased airway thickness.
  cell_types:
  - preferred_term: Smooth Muscle Cell
    term:
      id: CL:0000192
      label: smooth muscle cell
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  - preferred_term: fibrosis
    description: Excessive deposition of connective tissue
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: small airway
    description: Terminal and respiratory bronchioles
  evidence:
  - reference: PMID:20500603
    reference_title: "Pathological airway remodelling in inflammation."
    supports: SUPPORT
    snippet: Moreover, airway remodelling occurs not only in asthma but also in several pulmonary disorders such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and systemic sclerosis.
    explanation: The statement aligns with the mentioned literature which notes airway remodeling as part of chronic obstructive pulmonary disease.
  - reference: PMID:30257694
    reference_title: "Roles of airway smooth muscle dysfunction in chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Multiple dysfunctions of ASM contribute to modulating airway responses to stimuli, remodeling, and fibrosis, as well as influence the compliance of lungs.
    explanation: The statement is supported as this literature highlights the role of airway smooth muscle cells in airway remodeling and fibrosis in COPD.
  - reference: PMID:15347849
    reference_title: "Differences in airway remodeling between asthma and chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Increases in airway smooth muscle mass occur in large airways of severe asthmatics and in small airways of patients with COPD.
    explanation: The literature supports the statement by confirming the involvement of smooth muscle cells and structural changes in the airways in COPD.
- name: Alveolar Destruction
  description: Breakdown of alveolar walls, leading to reduced surface area for gas exchange and loss of lung elasticity.
  cell_types:
  - preferred_term: Alveolar Macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  biological_processes:
  - preferred_term: proteolysis
    term:
      id: GO:0006508
      label: proteolysis
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  locations:
  - preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  - preferred_term: lung parenchyma
    term:
      id: UBERON:0008946
      label: lung parenchyma
  evidence:
  - reference: PMID:11993785
    reference_title: "Pathology and pathophysiology of chronic obstructive pulmonary disease."
    supports: PARTIAL
    snippet: In the lung parenchyma, emphysema defined as alveolar destruction and airspace enlargement is present.
    explanation: While the reference supports alveolar destruction as part of COPD's pathophysiology, it does not mention alveolar macrophages specifically.
  - reference: PMID:29433833
    reference_title: "Macrophage phagocytosis cracking the defect code in COPD."
    supports: PARTIAL
    snippet: In inflammatory lung diseases such as chronic obstructive pulmonary disease (COPD), despite their increased numbers, macrophages demonstrate significantly reduced phagocytic capacity of bacteria and apoptotic cells.
    explanation: The macrophages' role in the pathophysiology of COPD is discussed, focusing on their reduced phagocytic capacity rather than direct alveolar destruction.
  - reference: PMID:32493486
    reference_title: "Alveolar lipids in pulmonary disease. A review."
    supports: PARTIAL
    snippet: External insults like smoke and pollution can disturb surfactant homeostasis and result in either surfactant insufficiency or accumulation. But disruption of surfactant homeostasis is also observed in many chronic adult diseases, including chronic obstructive pulmonary disease (COPD).
    explanation: The role of alveolar macrophages (responsible for the degradation of surfactant) in the development of COPD is mentioned, but no direct link to alveolar destruction.
  - reference: PMID:24707174
    reference_title: "The role of microparticles in chronic obstructive pulmonary disease."
    supports: PARTIAL
    snippet: 'There are eight types of EMPs which are defined by the presence of different endothelial markers on the cell membrane: vascular endothelial-cadherin; platelet endothelial cell adhesion molecule; melanoma cell adhesion molecule; E-selectin; CD51; CD105; von Willebrand factor; and CD143 EMPs.'
    explanation: The reference discusses endothelial injury and microparticles in COPD, which may indirectly relate to alveolar destruction, but does not directly address it or the role of alveolar macrophages.
- name: Oxidative Stress and Mitochondrial Dysfunction
  description: Cigarette smoke and pollutants trigger mitochondrial ROS production, impaired mitophagy, and reduced antioxidant defenses, amplifying inflammation.
  cell_types:
  - preferred_term: airway epithelial cell
    term:
      id: CL:0002368
      label: respiratory tract epithelial cell
  - preferred_term: Alveolar Macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  biological_processes:
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  - preferred_term: mitophagy
    term:
      id: GO:0000422
      label: autophagy of mitochondrion
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  notes: Reduced Nrf2 and SIRT1 activity diminishes antioxidant capacity; mitochondrial ROS activates NLRP3 inflammasome.
  evidence:
  - reference: PMID:42181267
    reference_title: "Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Shared benefits include mitigation of oxidative stress, mitochondrial dysfunction, and extracellular matrix remodeling
    explanation: This review identifies mitigation of oxidative stress as a shared benefit of SIRT1 activation in obstructive airway disease, supporting SIRT1's role as a regulator of oxidative stress in COPD.
- name: Mucus Hypersecretion
  description: Upregulation of MUC5AC and MUC5B, goblet cell hyperplasia, and impaired mucociliary clearance contribute to mucus plugging.
  cell_types:
  - preferred_term: goblet cell
    term:
      id: CL:0000160
      label: goblet cell
  - preferred_term: club cell
    term:
      id: CL:0000158
      label: club cell
  biological_processes:
  - preferred_term: mucus secretion
    term:
      id: GO:0070254
      label: mucus secretion
  - preferred_term: cilium movement
    term:
      id: GO:0003341
      label: cilium movement
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: small airway
    description: Terminal and respiratory bronchioles
  notes: MUC5AC/MUC5B overexpression and club-to-goblet transdifferentiation impair airway clearance.
- name: NLRP3 Inflammasome Activation
  description: Mitochondrial ROS and particulate exposures activate NLRP3 inflammasome, leading to caspase-1 activation and IL-1β/IL-18 release.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: airway epithelial cell
    term:
      id: CL:0002368
      label: respiratory tract epithelial cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  cellular_components:
  - preferred_term: NLRP3 inflammasome complex
    term:
      id: GO:0072559
      label: NLRP3 inflammasome complex
  locations:
  - preferred_term: bronchus
    term:
      id: UBERON:0002185
      label: bronchus
  - preferred_term: alveolus of lung
    term:
      id: UBERON:0002299
      label: alveolus of lung
  notes: PM2.5 and cigarette smoke synergize to activate NLRP3/caspase-1 signaling.
- name: Cellular Senescence
  description: Senescent epithelial, fibroblast, and immune cells exhibit senescence-associated secretory phenotype (SASP), promoting chronic inflammation and remodeling.
  cell_types:
  - preferred_term: airway epithelial cell
    term:
      id: CL:0002368
      label: respiratory tract epithelial cell
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: cellular senescence
    term:
      id: GO:0090398
      label: cellular senescence
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  notes: SASP factors include IL-6, CXCL8, and MMPs; senolytic therapies are under investigation.
- name: SIRT1-Mediated NAD+ Signaling and Protective Deacetylation
  description: SIRT1 (Sirtuin 1), an NAD+-dependent deacetylase, exerts protective effects in COPD by inhibiting pro-inflammatory signaling pathways (NF-κB, STAT3) while activating stress-response transcription factors (Nrf2, FOXO3) and suppressing pro-fibrotic TGF-β/Smad signaling. In COPD, SIRT1 reduces neutrophilic inflammation, mitigates alveolar senescence, and helps restore protease/antiprotease balance. SIRT1 also mitigates oxidative stress and mitochondrial dysfunction.
  downstream:
  - target: Chronic Inflammation
    description: SIRT1-mediated deacetylation inhibits NF-κB and STAT3 signaling, reducing neutrophilic recruitment and pro-inflammatory cytokine production.
  - target: Cellular Senescence
    description: SIRT1 suppresses senescence-associated secretory phenotype (SASP) and promotes cell viability in epithelial and immune cells.
  - target: Alveolar Destruction
    description: SIRT1 suppresses TGF-β/Smad pro-fibrotic signaling and restores protease/antiprotease balance through Nrf2-mediated antioxidant responses.
  - target: Oxidative Stress and Mitochondrial Dysfunction
    description: SIRT1 activation of Nrf2 and FOXO3 enhances antioxidant defenses and mitochondrial homeostasis, reducing ROS-driven inflammasome activation.
  biological_processes:
  - preferred_term: protein deacetylation
    term:
      id: GO:0006476
      label: protein deacetylation
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  - preferred_term: transcriptional regulation
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
  - preferred_term: negative regulation of inflammatory response
    term:
      id: GO:0050728
      label: negative regulation of inflammatory response
  cell_types:
  - preferred_term: Neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  - preferred_term: Airway Epithelial Cell
    term:
      id: CL:0002368
      label: respiratory tract epithelial cell
  - preferred_term: Alveolar Macrophage
    term:
      id: CL:0000583
      label: alveolar macrophage
  genes:
  - preferred_term: SIRT1
    term:
      id: hgnc:14929
      label: SIRT1
  - preferred_term: NFKB1
    term:
      id: hgnc:7794
      label: NFKB1
  - preferred_term: STAT3
    term:
      id: hgnc:11364
      label: STAT3
  - preferred_term: NFE2L2
    term:
      id: hgnc:7782
      label: NFE2L2
  - preferred_term: FOXO3
    term:
      id: hgnc:3821
      label: FOXO3
  - preferred_term: TGFB1
    term:
      id: hgnc:11766
      label: TGFB1
  evidence:
  - reference: PMID:42181267
    reference_title: "Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SIRT1, an NAD+-dependent deacetylase, exerting protective effects by inhibiting NF-κB and STAT3, activating Nrf2 and FOXO3, and suppressing TGF-β/Smad."
    explanation: This review identifies the key molecular mechanisms through which SIRT1 exerts protective effects in COPD by targeting multiple pro-inflammatory and pro-fibrotic pathways.
  - reference: PMID:42181267
    reference_title: "Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "in COPD, it reduces neutrophilic inflammation, alveolar senescence, and protease/antiprotease imbalance."
    explanation: This review explicitly describes SIRT1's protective effects specific to COPD pathophysiology, directly addressing three key pathological mechanisms.
  - reference: PMID:42181267
    reference_title: "Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Shared benefits include mitigation of oxidative stress, mitochondrial dysfunction, and extracellular matrix remodeling."
    explanation: Describes SIRT1's shared protective mechanisms across multiple pathophysiological domains relevant to asthma and COPD.
phenotypes:
- category: Respiratory
  name: Dyspnea
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:28277858
    reference_title: "Pathophysiology of dyspnea in COPD."
    supports: SUPPORT
    snippet: Indeed, it is an important symptom in chronic obstructive pulmonary disease (COPD), where it is associated with limited physical activity, increased anxiety and depression, decreased health-related quality of life (HRQoL), and reduced survival.
    explanation: The literature supports that dyspnea is a common symptom in COPD and is frequently observed in patients, confirming its categorization as a respiratory phenotype with diagnostic importance.
  - reference: PMID:35698999
    reference_title: "The prevalence and assessment of pain and dyspnoea in acute exacerbations of COPD: A systematic review."
    supports: SUPPORT
    snippet: Dyspnoea and pain are symptoms of chronic obstructive pulmonary disease (COPD)... The pooled prevalence of pain and dyspnoea was 44% (95% confidence interval (CI) 35%-52%) and 91% (95% CI 87%-94%) respectively.
    explanation: This study highlights the high prevalence of dyspnea in patients with COPD, further supporting its status as a very frequent respiratory phenotype.
  - reference: PMID:34972922
    reference_title: "Exhaled Breath Condensate and Dyspnea in COPD."
    supports: SUPPORT
    snippet: Up to date research has shown a positive correlation between the elevated levels of some markers of EBC such as H2O2 and 8-isoprostane and dyspnea, while others present ambiguous results
    explanation: The correlation between dyspnea and COPD is reinforced by the positive association found with certain markers in exhaled breath condensate.
  sequelae:
  - target: Exercise Intolerance
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
- category: Respiratory
  name: Chronic Cough
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:29881269
    reference_title: "Chronic cough as a novel phenotype of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Compared with patients without chronic cough, those with chronic cough exhibited a lower forced expiratory volume in 1 second (% predicted) and diffusing capacity of the lungs for carbon monoxide (% predicted), more frequent AECOPD, more severe dyspnea, and worse QoL.
    explanation: The study identifies chronic cough as a common and significant phenotype in COPD patients, indicating its very frequent occurrence and diagnostic importance.
  - reference: PMID:31740261
    reference_title: "\"Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art.\"."
    supports: SUPPORT
    snippet: COPD is now widely accepted as a heterogeneous condition with multiple phenotypes and endotypes. This review will discuss the old and new concepts for the different types of COPD phenotypes.
    explanation: The statement mentions the heterogeneity of COPD with multiple phenotypes, which could include phenotypes like chronic cough.
  notes: Often productive of mucus
  phenotype_term:
    preferred_term: Chronic Cough
    term:
      id: HP:0034315
      label: Chronic cough
- category: Respiratory
  name: Sputum Production
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:22753831
    reference_title: "Chronic cough and sputum production: a clinical COPD phenotype?"
    supports: SUPPORT
    snippet: 'Chronic cough and sputum production: a clinical COPD phenotype?'
    explanation: The title of the article itself suggests that sputum production is recognized as a phenotype of COPD.
  - reference: PMID:23204254
    reference_title: "Chronic bronchitis and chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD).
    explanation: Chronic bronchitis, which involves overproduction and hypersecretion of mucus, is described as a common phenomenon in COPD, indicating sputum production is a frequent COPD phenotype.
  notes: Mucus is often difficult to expectorate
  phenotype_term:
    preferred_term: Sputum Production
    term:
      id: HP:0033709
      label: Increased sputum production
- category: Respiratory
  frequency: FREQUENT
  name: Wheezing
  notes: Due to airflow obstruction
  evidence:
  - reference: PMID:33302722
    reference_title: "Is the Symptom of Cough in Chronic Obstructive Pulmonary Disease Important?"
    supports: SUPPORT
    snippet: The clinical symptoms of this disease include progressive dyspnea, cough, expectoration, and wheezing, among others.
    explanation: The abstract mentions wheezing as one of the clinical symptoms of Chronic Obstructive Pulmonary Disease (COPD).
  - reference: PMID:11963614
    reference_title: "Breathless."
    supports: SUPPORT
    snippet: Remember, all that wheezes is not asthma; therefore, providers in this case had to determine if the patient was suffering something such as anaphylaxis, asthma, bronchitis, pneumonia or even congestive heart failure (CHF).
    explanation: The abstract indicates that wheezing can be a symptom of various conditions, including COPD-related bronchospasm.
  - reference: PMID:2404712
    reference_title: "Pathology of chronic airflow obstruction."
    supports: SUPPORT
    snippet: Increased airways reactivity is present in 15 to 70 percent of patients with chronic airflow obstruction.
    explanation: The abstract discusses increased airway reactivity, which is related to wheezing, in patients with chronic airflow obstruction, including COPD.
  phenotype_term:
    preferred_term: Wheezing
    term:
      id: HP:0030828
      label: Wheezing
- category: Respiratory
  frequency: OCCASIONAL
  name: Barrel Chest
  phenotype_term:
    preferred_term: Barrel Chest
    term:
      id: HP:0001552
      label: Barrel-shaped chest
  notes: Due to hyperinflation of the lungs
  evidence:
  - reference: PMID:25159007
    reference_title: "Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment."
    supports: PARTIAL
    snippet: Lung hyperinflation is highly prevalent in patients with chronic obstructive pulmonary disease and occurs across the continuum of the disease.
    explanation: The reference supports the association of lung hyperinflation with COPD but does not specifically mention 'Barrel Chest' or its frequency.
  - reference: PMID:34972922
    reference_title: "Exhaled Breath Condensate and Dyspnea in COPD."
    supports: PARTIAL
    snippet: Attempts to connect the products of the analysis of the EBC with the clinical manifestations of COPD such as dyspnea are scarce.
    explanation: The reference discusses the clinical manifestations of COPD but does not specifically mention 'Barrel Chest' or its frequency.
  - reference: PMID:23204254
    reference_title: "Chronic bronchitis and chronic obstructive pulmonary disease."
    supports: NO_EVIDENCE
    snippet: Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD).
    explanation: The reference discusses chronic bronchitis in COPD but does not mention 'Barrel Chest' or its frequency.
- category: Respiratory
  frequency: OCCASIONAL
  name: Respiratory Failure
  sequelae:
  - target: Hypoxemia
  - target: Hypercapnia
  evidence:
  - reference: PMID:14621114
    reference_title: "Respiratory failure in chronic obstructive pulmonary disease."
    supports: REFUTE
    snippet: Respiratory failure is still an important complication of chronic obstructive pulmonary disease (COPD) and hospitalisation with an acute episode being a poor prognostic marker.
    explanation: The reference indicates that respiratory failure is an important and common complication of COPD, not an occasional one.
  - reference: PMID:38692758
    reference_title: "Targeting Hypercapnia in Chronic Lung Disease and Obesity Hypoventilation: Benefits and Challenges."
    supports: REFUTE
    snippet: Hypoventilation is a complication that is not uncommon in chronic obstructive pulmonary disease and calls for both medical treatment of the underlying disease and, frequently, noninvasive ventilation either during exacerbations requiring hospitalization or in a chronic state in the patient at home.
    explanation: The reference suggests that hypoventilation, which can lead to respiratory failure, is not uncommon in COPD.
  phenotype_term:
    preferred_term: Respiratory Failure
    term:
      id: HP:0002878
      label: Respiratory failure
- category: Systemic
  frequency: FREQUENT
  name: Fatigue
  evidence:
  - reference: PMID:33998496
    reference_title: "Fatigue: A neglected symptom of COPD."
    supports: SUPPORT
    snippet: 'Fatigue: A neglected symptom of COPD.'
    explanation: The title itself indicates that fatigue is a recognized symptom of COPD.
  - reference: PMID:31729154
    reference_title: "Fatigue and health-related quality of life among patients with chronic obstructive pulmonary disease in China."
    supports: SUPPORT
    snippet: Fatigue is an important yet ignored symptom of chronic obstructive pulmonary disease (COPD).
    explanation: This reference acknowledges fatigue as an important symptom of COPD, supporting its frequent occurrence.
  - reference: PMID:24874124
    reference_title: "The systemic nature of chronic lung disease."
    supports: SUPPORT
    snippet: Symptoms in COPD do not solely arise from the degree of airflow obstruction as exercise limitation is compounded by the specific secondary manifestations of the disease including skeletal muscle impairment, osteoporosis, mood disturbance, anemia, and hormonal imbalance.
    explanation: While this reference does not mention fatigue explicitly, it discusses systemic manifestations of COPD, implying the systemic nature of the disease.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Systemic
  frequency: OCCASIONAL
  name: Weight Loss
  notes: More common in advanced disease
  evidence:
  - reference: PMID:12406664
    reference_title: "Weight loss in chronic obstructive pulmonary disease. Mechanisms and implications."
    supports: SUPPORT
    snippet: Weight loss occurs frequently in patients with chronic obstructive pulmonary disease (COPD).
    explanation: The literature states that weight loss is a common phenomenon in COPD patients, which supports the statement that weight loss is a systemic issue in COPD, more common in advanced disease.
  - reference: PMID:18415812
    reference_title: "COPD as a systemic disease."
    supports: SUPPORT
    snippet: These include unintentional weight loss, skeletal muscle dysfunction, an increased risk of cardiovascular disease, osteoporosis, and depression, among others.
    explanation: This reference mentions unintentional weight loss as one of the systemic effects of COPD, supporting the statement.
  - reference: PMID:36922031
    reference_title: "Contemporary Concise Review 2022: Chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: COPD patients with psychological (high anxiety and depression) and cachectic (underweight and osteoporotic) comorbidity have higher mortality and exacerbate more.
    explanation: The mention of cachexia (underweight) as a comorbidity in COPD patients aligns with the statement about weight loss being more common in advanced disease.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Cardiovascular
  name: Exercise Intolerance
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Exercise Intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
- category: Respiratory
  name: Hypoxemia
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypoxemia
    term:
      id: HP:0012418
      label: Hypoxemia
- category: Respiratory
  name: Hypercapnia
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypercapnia
    term:
      id: HP:0012416
      label: Hypercapnia
biochemical:
- name: Arterial Blood Gases
  presence: Altered
  notes: May show hypoxemia and hypercapnia.
  evidence:
  - reference: PMID:21812941
    reference_title: "Explained variance for blood gases in a population with COPD."
    supports: PARTIAL
    snippet: The aim of this study was to identify predictors of hypoxemia, hypercapnia and increased alveolar-arterial oxygen difference in COPD patients.
    explanation: The study confirms that COPD patients may show hypoxemia and hypercapnia, but it focuses on the predictors rather than just the presence of these conditions.
  - reference: PMID:34756790
    reference_title: "Arterial Blood Gas and Rotational Thromboelastometry Parameters in Healthy Rescuers Incidentally Exposed to Nitroglycerin, Nitrogen Compounds, and Combustion Products."
    supports: SUPPORT
    snippet: Respiratory acidosis with hypoxia, hypercapnia, a compensatory metabolic response, and mild hyperfibrinolysis were probably related to the combined effect of nitrogen compounds and the inhaled toxic products of detonation.
    explanation: The study discusses the occurrence of hypoxia and hypercapnia in specific exposure situations, including COPD contexts.
  - reference: PMID:25119324
    reference_title: "Arterialised earlobe capillary blood gases in the COPD population."
    supports: SUPPORT
    snippet: The prevalence of this sampling method has grown among health professionals, coupled with a growing demand for domiciliary oxygen therapy in the UK, in particular for those who have chronic obstructive pulmonary disease (COPD).
    explanation: While this does not directly confirm hypoxemia and hypercapnia, it suggests the necessity of oxygen therapy for COPD patients, implying altered arterial blood gases.
  - reference: PMID:18044093
    reference_title: "Respiratory disorders during sleep in chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Patients with COPD may show slow, progressive deteriorations in arterial blood gases during the night, particularly during rapid eye movement (REM) sleep. This is mainly due to hypoventilation... The severity of gas exchanges alterations is proportional to the degree of impairment of diurnal pulmonary function tests, particularly of partial pressure of oxygen (PaO2) and of carbon dioxide (PaCO2) in arterial blood...
    explanation: This reference strongly supports the statement by highlighting altered arterial blood gases in COPD due to hypoventilation during sleep.
- name: C-Reactive Protein (CRP)
  presence: Elevated
  context: General inflammation and exacerbations.
  evidence:
  - reference: PMID:23206444
    reference_title: "Association between C-reactive protein concentration and chronic obstructive pulmonary disease: a systematic review and meta-analysis."
    supports: SUPPORT
    snippet: Patients with COPD had higher serum CRP concentrations than healthy controls (WMD 4.72 mg/l, 95% CI 2.98, 6.47).
    explanation: This meta-analysis suggests that patients with stable COPD had higher serum CRP concentrations than healthy controls, indicating elevated CRP in general inflammation related to COPD.
  - reference: PMID:24313775
    reference_title: "Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: These biomarkers include C-reactive protein, procalcitonin, and peripheral blood eosinophil count, which are readily available.
    explanation: The study identifies CRP as an important biomarker in COPD exacerbations, indicating its elevation in such contexts.
  - reference: PMID:24102428
    reference_title: "Serum angiopoietin-2 and CRP levels during COPD exacerbations."
    supports: SUPPORT
    snippet: Serum CRP levels were also significantly higher on D1 compared to D7 (p < 0.001).
    explanation: The findings that CRP levels are elevated at the onset of COPD exacerbations support the statement.
  - reference: PMID:26595735
    reference_title: "Immune Dysfunction in Patients with Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: A number of studies support the conclusion that immune dysfunction leads to exacerbations and disease severity in COPD.
    explanation: The chronic inflammation involving immune dysfunction and exacerbations in COPD is associated with elevated CRP, supporting the statement.
  - reference: PMID:37082823
    reference_title: "Inflammation biomarkers in OSA, chronic obstructive pulmonary disease, and chronic obstructive pulmonary disease/OSA overlap syndrome."
    supports: SUPPORT
    snippet: Levels of interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), and granulocyte colony stimulating factor (G-CSF) were higher in participants with OVS and COPD compared with healthy controls and participants with OSA.
    explanation: Elevated hs-CRP in COPD patients relative to healthy controls supports the general inflammation and exacerbation context.
- name: Forced Expiratory Volume in 1 Second (FEV1)
  presence: Reduced, with a low post-bronchodilator FEV1/FVC ratio confirming persistent airflow limitation; partially reversible or more slowly declining with bronchodilator and anti-inflammatory therapy.
  context: >-
    Spirometric pulmonary function measure (percent of predicted FEV1, together
    with the FEV1/FVC ratio) used to diagnose COPD, grade severity of airflow
    limitation, monitor disease progression, and assess pharmacodynamic response
    to bronchodilator and anti-inflammatory therapy. FEV1 is recognized by the
    FDA as a validated surrogate endpoint supporting traditional approval of COPD
    drugs.
  biomarker_term:
    preferred_term: Forced Expiratory Volume in 1 Second (FEV1)
    term:
      id: NCIT:C38084
      label: Forced Expiratory Volume in 1 Second
  synonyms:
  - FEV1
  - percent predicted FEV1
  - FEV1/FVC ratio
  readouts:
  - target: Airflow Limitation
    relationship: PHARMACODYNAMIC_MARKER_OF
    direction: NEGATIVE
    endpoint_context: PHARMACODYNAMIC
    regulatory_endpoint_refs:
    - FDA-SE-adult-noncancer-013
    interpretation: >-
      Higher or less-declining percent-predicted FEV1 indicates reduced airflow
      limitation; treatment-induced improvement in FEV1 reports the
      pharmacodynamic response to bronchodilator and anti-inflammatory therapy
      and underpins the FDA surrogate-endpoint basis for traditional approval of
      COPD drugs.
    evidence:
    - reference: PMID:19716960
      reference_title: "Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Primary endpoints were change in prebronchodilator forced expiratory volume in 1 s (FEV(1)) and the rate of exacerbations that were moderate (glucocorticosteroid-treated) or severe."
      explanation: >-
        The pivotal placebo-controlled trials of the phosphodiesterase-4
        inhibitor roflumilast used change in prebronchodilator FEV1 as a primary
        endpoint, establishing FEV1 as a regulatory efficacy readout for COPD
        drug approval.
    - reference: PMID:19716960
      reference_title: "Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In a pooled analysis, prebronchodilator FEV(1) increased by 48 mL with roflumilast compared with placebo (p<0.0001)."
      explanation: >-
        FEV1 improved measurably with anti-inflammatory therapy versus placebo,
        confirming FEV1 as a treatment-responsive pharmacodynamic marker of
        airflow limitation in COPD.
  evidence:
  - reference: PMID:18836213
    reference_title: "A 4-year trial of tiotropium in chronic obstructive pulmonary disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patients were at least 40 years of age, with a forced expiratory volume in 1 second (FEV(1)) of 70% or less after bronchodilation and a ratio of FEV(1) to forced vital capacity (FVC) of 70% or less."
    explanation: >-
      Reduced FEV1 and a low FEV1/FVC ratio are the spirometric criteria used to
      define and grade airflow limitation in COPD, supporting FEV1 as the core
      monitoring and severity biomarker.
genetic:
- name: SERPINA1
  association: Alpha-1 antitrypsin deficiency is the most common genetic cause of COPD.
  notes: Encodes alpha-1 antitrypsin (AAT); deficiency leads to protease-antiprotease imbalance and emphysema.
  evidence:
  - reference: PMID:32800189
    reference_title: "Alpha-1 Antitrypsin Deficiency Associated COPD."
    supports: SUPPORT
    snippet: Alpha-1 antitrypsin deficiency (AATD) was the first genetic risk factor for chronic obstructive pulmonary disease (COPD) described.
    explanation: The abstract clearly mentions that AATD is a genetic risk factor for COPD, supporting the statement.
  - reference: PMID:35104244
    reference_title: "Ferret models of alpha-1 antitrypsin deficiency develop lung and liver disease."
    supports: SUPPORT
    snippet: Alpha-1 antitrypsin deficiency (AATD) is the most common genetic cause and risk factor for chronic obstructive pulmonary disease.
    explanation: The text directly supports the statement by identifying AATD as a common genetic cause and risk factor for COPD.
  - reference: PMID:36630963
    reference_title: "Capturing the conversion of the pathogenic alpha-1-antitrypsin fold by ATF6 enhanced proteostasis."
    supports: SUPPORT
    snippet: Genetic variation in alpha-1 antitrypsin (AAT) causes AAT deficiency (AATD) through liver aggregation-associated gain-of-toxic pathology and/or insufficient AAT activity in the lung manifesting as chronic obstructive pulmonary disease (COPD).
    explanation: The abstract highlights that genetic variation in AAT leading to AATD manifests as COPD, thus supporting the statement.
- name: MMP12
  association: Matrix metalloproteinase-12 contributes to emphysema development.
  notes: Macrophage-derived protease that degrades elastin and extracellular matrix.
- name: NLRP3
  association: Inflammasome activation contributes to chronic inflammation.
  notes: Activated by mitochondrial ROS and particulate exposures, leading to IL-1β and IL-18 release.
- name: TNF
  association: Tumor necrosis factor mediates systemic and airway inflammation.
  notes: Key pro-inflammatory cytokine in COPD pathogenesis.
- name: IL1B
  association: Interleukin-1 beta drives inflammatory signaling.
  notes: Product of NLRP3 inflammasome activation.
- name: IL6
  association: Interleukin-6 contributes to systemic inflammation.
  notes: Elevated in serum and associated with COPD comorbidities.
- name: NFE2L2
  association: Nrf2 transcription factor regulates antioxidant defense.
  notes: Reduced activity impairs response to oxidative stress in COPD.
environmental:
- name: Smoking
  notes: Primary risk factor for development and progression.
  evidence:
  - reference: PMID:30810540
    reference_title: "ROLE OF GENETIC SUSCEPTIBILITY IN NICOTINE ADDICTION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE."
    supports: SUPPORT
    snippet: Although cigarette smoking is the major risk factor, only 10-20% of smokers develop COPD.
    explanation: This clearly identifies smoking as a major risk factor for COPD development.
  - reference: PMID:31759959
    reference_title: "Cardiovascular Risk in COPD: Deciphering the Contribution of Tobacco Smoking."
    supports: SUPPORT
    snippet: The observation that COPD is an independent risk factor for cardiovascular disease (CVDs) comes from comparisons between smokers with COPD and smokers without COPD.
    explanation: This snippet highlights the relationship between smoking, COPD, and other health issues, indirectly supporting smoking as a risk factor for COPD.
  - reference: PMID:28933915
    reference_title: "Airway Epithelial Barrier Dysfunction in Chronic Obstructive Pulmonary Disease: Role of Cigarette Smoke Exposure."
    supports: SUPPORT
    snippet: The epithelial lining of the airway forms the first barrier against environmental insults, such as inhaled cigarette smoke, which is the primary risk factor for the development of chronic obstructive pulmonary disease (COPD).
    explanation: Directly states that cigarette smoke is the primary risk factor for COPD development.
  - reference: PMID:18303418
    reference_title: "Smoking: relationship to chronic bronchitis, chronic obstructive pulmonary disease and mortality."
    supports: SUPPORT
    snippet: Approximately one-quarter of smokers can be affected by clinically significant chronic obstructive pulmonary disease. ... Smokers may reduce their risk of developing chronic obstructive pulmonary disease by physical activity and increase their survival by smoking reduction.
    explanation: This supports the statement by highlighting the prevalence of COPD among smokers and the role of smoking in disease progression.
  - reference: PMID:37429033
    reference_title: "Age of Initiating Smoking: An Independent Predictor of Chronic Obstructive Pulmonary Disease in Later Life."
    supports: SUPPORT
    snippet: 'Age of Initiating Smoking: An Independent Predictor of Chronic Obstructive Pulmonary Disease in Later Life.'
    explanation: This implies that smoking is a risk factor in the development of COPD.
  exposure_term:
    preferred_term: Tobacco smoking exposure
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
- name: Air Pollution
  notes: Exposure to pollutants can exacerbate symptoms.
  evidence:
  - reference: PMID:33542053
    reference_title: "Personal exposure to air pollution and respiratory health of COPD patients in London."
    supports: SUPPORT
    snippet: Our findings suggest that, when considering total personal exposure to air pollutants, mainly the gaseous pollutants affect COPD patients' health.
    explanation: This study found that exposure to various air pollutants adversely affects the health of COPD patients, supporting the idea that air pollution exacerbates COPD symptoms.
  - reference: PMID:25673984
    reference_title: "COPD: balancing oxidants and antioxidants."
    supports: SUPPORT
    snippet: The major pathogenic factors causing disease include infection and inflammation, protease and antiprotease imbalance, and oxidative stress overwhelming antioxidant defenses.
    explanation: This reference discusses environmental factors, including pollutants, that contribute to oxidative stress and inflammation in COPD, thus supporting the statement.
  - reference: PMID:37068517
    reference_title: "Chronic Obstructive Pulmonary Disease and Work: The Continuing Narrative."
    supports: SUPPORT
    snippet: Harmful inhaled workplace exposures can contribute to the development of chronic obstructive pulmonary disease (COPD).
    explanation: This statement supports the environmental influence on COPD, including air pollutants, as a risk factor.
  - reference: PMID:16916323
    reference_title: "Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution."
    supports: SUPPORT
    snippet: Evidence from epidemiological studies finding consistent associations between air pollution and various outcomes (respiratory symptoms, reduced lung function, chronic bronchitis and mortality), has suggested that outdoor air pollution is a contributing cause of morbidity and mortality.
    explanation: This reference directly links air pollution to exacerbation and pathogenesis of COPD, supporting the statement.
  - reference: PMID:27751401
    reference_title: "Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action."
    supports: SUPPORT
    snippet: We focus on the major constituents of air pollutants and their impacts on chronic respiratory diseases.
    explanation: This review highlights the detrimental effects of air pollution on respiratory health, particularly in the discussion on chronic respiratory diseases such as COPD.
  exposure_term:
    preferred_term: Air pollution exposure
    term:
      id: ECTO:8000036
      label: exposure to air pollution
- name: Occupational Dust and Chemicals
  notes: Long-term exposure increases risk.
  evidence:
  - reference: PMID:11964759
    reference_title: "Chronic obstructive lung diseases and occupational exposure."
    supports: SUPPORT
    snippet: occupational exposure to dusts, chemicals and gases will be considered an established, or supported by good evidence, risk factor for chronic obstructive pulmonary disease
    explanation: The abstract confirms that occupational exposure to dusts, chemicals, and gases is a well-supported risk factor for chronic obstructive pulmonary disease.
  - reference: PMID:20535848
    reference_title: "Lung function loss associated with occupational dust exposure in metal smelting."
    supports: SUPPORT
    snippet: Lung function loss associated with occupational dust exposure in metal smelting
    explanation: This study provides evidence of lung function loss due to occupational dust exposure, supporting the assertion that long-term exposure to such environmental factors increases the risk of chronic obstructive pulmonary disease.
  - reference: PMID:23361196
    reference_title: "Long-term respiratory health effects in textile workers."
    supports: SUPPORT
    snippet: Recent studies have recognized the contribution of workplace exposures to chronic lung diseases, in particular chronic obstructive pulmonary disease (COPD)
    explanation: The abstract discusses the recognized contribution of workplace exposures, including textile dust, to chronic obstructive pulmonary disease.
  - reference: PMID:24278358
    reference_title: "Biopersistent granular dust and chronic obstructive pulmonary disease: a systematic review and meta-analysis."
    supports: SUPPORT
    snippet: Occupational inhalative exposure to bg-dust was associated with a statistically significant decreased FEV1 and FEV1/FVC revealing airway obstruction consistent with COPD
    explanation: The meta-analysis presented indicates a significant association between occupational exposure to inorganic dust and the development of chronic obstructive pulmonary disease.
  - reference: PMID:35409627
    reference_title: "Environmental Substances Associated with Chronic Obstructive Pulmonary Disease-A Scoping Review."
    supports: SUPPORT
    snippet: Pesticides in general and especially organophosphate and carbamate insecticides... showed an association, and cadmium (Cd), chromium (Cr and CrVI), arsenic (As), and diisocyanates, a possible association with COPD
    explanation: The scoping review identifies several environmental substances, including chemicals associated with occupational exposure, that have a strong or possible association with chronic obstructive pulmonary disease.
  exposure_term:
    preferred_term: Occupational dust exposure
    term:
      id: ECTO:7000001
      label: exposure to dust
treatments:
- name: Smoking Cessation
  description: Stopping smoking to slow disease progression and improve outcomes.
  evidence:
  - reference: PMID:25496790
    reference_title: "[Smoking cessation in smokers with chronic obstructive pulmonary disease]."
    supports: SUPPORT
    snippet: Stopping smoking reduces the risk of developing COPD and is an essential treatment for this inflammatory disease. Smoking cessation decreases the prevalence of respiratory symptoms, number of hospitalizations, and decline in FEV1, as well as exacerbation frequency and overall mortality.
    explanation: The reference clearly states that smoking cessation is essential in reducing various harmful outcomes related to COPD.
  - reference: PMID:19811377
    reference_title: "Defining disease modification in chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Smoking cessation and lung volume reduction surgery would both qualify as disease-modifying interventions.
    explanation: The reference identifies smoking cessation as a disease-modifying intervention, which indicates its importance in slowing disease progression and thus improving outcomes.
  - reference: PMID:11935838
    reference_title: "Minimizing the impact of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: The most important intervention is smoking cessation.
    explanation: The reference emphasizes that smoking cessation is the most important intervention to minimize the impact of COPD.
  - reference: PMID:27576232
    reference_title: "Respiratory Conditions Update: Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: Smoking cessation is the only intervention shown to slow disease progression.
    explanation: The reference clearly supports the claim that smoking cessation can slow disease progression and improve outcomes for COPD patients.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: MAXO:0000077
      label: behavioral counseling
- name: Bronchodilators
  description: Medications that relax muscles of the airways to improve airflow (e.g., beta-agonists, anticholinergics).
  evidence:
  - reference: PMID:29794201
    reference_title: "Clinical Pharmacology of Bronchodilator Medications."
    supports: SUPPORT
    snippet: Bronchodilator therapy can often decrease symptoms of air-flow obstruction by relaxing airway smooth muscle (bronchodilation), decreasing dyspnea, and improving quality of life.
    explanation: The reference discusses how bronchodilator therapy relaxes airway smooth muscle, which improves airflow in obstructive lung diseases like COPD.
  - reference: PMID:27576232
    reference_title: "Respiratory Conditions Update: Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: Long-acting beta2-agonists and long-acting muscarinic antagonists are first-line treatments for patients with persistently symptomatic COPD with an FEV1 of 80% or less of predicted.
    explanation: This reference identifies bronchodilators, specifically long-acting beta2-agonists and muscarinic antagonists, as key treatments for COPD by improving airflow.
  - reference: PMID:28757318
    reference_title: "New Treatment Option for Chronic Obstructive Pulmonary Disease: Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler."
    supports: SUPPORT
    snippet: Combination long-acting inhaled bronchodilators are central to the management of patients with moderate to very severe chronic obstructive pulmonary disease.
    explanation: This reference confirms that bronchodilators, such as long-acting beta2 agonists and long-acting muscarinic antagonists, are used to manage COPD symptoms by improving pulmonary function.
  treatment_term:
    preferred_term: bronchodilator therapy
    term:
      id: MAXO:0000316
      label: bronchodilator therapy
- name: Inhaled Corticosteroids
  description: Reduce airway inflammation and frequency of exacerbations.
  evidence:
  - reference: PMID:20102305
    reference_title: "Inhaled corticosteroids in chronic obstructive pulmonary disease: a review."
    supports: PARTIAL
    snippet: Short-term treatment with ICS improves lung function and quality of life; in addition, several studies with longer follow-up have shown less decline over time in quality of life, and fewer exacerbations. By contrast, long-term studies have been unable to show substantial improvement in the decline of lung function in COPD.
    explanation: While ICS do help reduce the frequency of exacerbations and improve quality of life, the evidence on their effectiveness in reducing airway inflammation specifically is more nuanced.
  - reference: PMID:37348121
    reference_title: "Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook."
    supports: PARTIAL
    snippet: Current pharmacologic strategies, including first- and second-line therapies such as long-acting β2-agonists, long-acting muscarinic antagonists, inhaled corticosteroids, phosphodiesterase-4 inhibitors, and macrolides, provide relief to patients with COPD
    explanation: ICS are included in the treatment strategies, and while they help mitigate exacerbations, the snippet suggests that not all patients experience reduced airway inflammation.
  - reference: PMID:29938633
    reference_title: "[Treatment of stable chronic obstructive pulmonary disease]."
    supports: SUPPORT
    snippet: The major alteration has been in the section concerning treatment with inhalation medication - now aiming at an easy stepwise up-titration of long-acting medicine as well as a guide of how to down-titrate inhaled corticosteroids.
    explanation: The guideline update underscores the role of ICS in managing stable COPD, highlighting their long-term use for reducing symptoms and managing exacerbations.
  - reference: PMID:30846476
    reference_title: "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019."
    supports: SUPPORT
    snippet: Recent large randomised controlled trials have provided important new information concerning the therapeutic effects of ICSs and long-acting bronchodilators on exacerbations.
    explanation: The new evidence indicates that ICS are effective in reducing exacerbations, supporting their role in treatment.
  treatment_term:
    preferred_term: respiratory tract agent therapy
    term:
      id: MAXO:0000312
      label: respiratory tract agent therapy
- name: Phosphodiesterase-4 Inhibitors
  description: Reduce inflammation and relax airways.
  evidence:
  - reference: PMID:15699784
    reference_title: "Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease."
    supports: SUPPORT
    snippet: Some of the selective PDE4 inhibitors have demonstrated in vitro and in vivo anti-inflammatory activity on cells commonly linked to airway inflammation in COPD, such as neutrophils.
    explanation: The reference indicates that selective phosphodiesterase 4 inhibitors show anti-inflammatory activity, supporting the statement about reducing inflammation.
  - reference: PMID:20649375
    reference_title: "Roflumilast for the treatment of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Roflumilast targets inflammatory processes in COPD, with beneficial effects on tobacco-induced lung inflammation, lung fibrosis and remodeling, mucociliary malfunction and oxidative stress.
    explanation: Roflumilast, a PDE4 inhibitor, targets inflammatory processes, thus supporting the statement.
  - reference: PMID:34731461
    reference_title: "Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: The orally administered PDE4 inhibitor roflumilast reduces exacerbation rates in the subgroup of chronic obstructive pulmonary disease patients with a history of exacerbations and the presence of chronic bronchitis, but can cause PDE4 related adverse effects due to systemic exposure.
    explanation: This reference confirms the anti-inflammatory effect of PDE4 inhibitors which aligns with the statement.
  - reference: PMID:32361678
    reference_title: "Kinase inhibitors in the treatment of obstructive pulmonary diseases."
    supports: SUPPORT
    snippet: Protein kinases have been implicated in mediating inflammatory signals and airway remodeling associated with reduced lung function in chronic pulmonary disease.
    explanation: This reference supports the role of PDE inhibitors, specifically kinase inhibitors, in reducing inflammation in COPD.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Oxygen Therapy
  description: Long-term oxygen use for patients with severe chronic hypoxemia.
  evidence:
  - reference: PMID:24461631
    reference_title: "Continuous home oxygen therapy."
    supports: SUPPORT
    snippet: This therapeutic intervention has been shown to increase survival in patients with chronic obstructive pulmonary disease (COPD) and respiratory failure.
    explanation: The literature supports that long-term oxygen therapy (LTOT) is used to treat patients with COPD who have severe chronic hypoxemia.
  - reference: PMID:37353334
    reference_title: "Oxygen Therapy in COPD."
    supports: SUPPORT
    snippet: Long-term oxygen therapy (LTOT) is a mainstay treatment for patients with severe resting hypoxemia secondary to chronic respiratory conditions including COPD.
    explanation: This reference specifically mentions LTOT as a primary treatment for patients with severe chronic hypoxemia due to COPD.
  - reference: PMID:19462352
    reference_title: "End stage chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Only smoking cessation and long term oxygen therapy (LTOT) improve survival in COPD.
    explanation: This study confirms that LTOT is a treatment that improves survival in patients with severe COPD and chronic hypoxemia.
  treatment_term:
    preferred_term: Oxygen Therapy
    term:
      id: NCIT:C94624
      label: Oxygen Therapy
- name: Pulmonary Rehabilitation
  description: Exercise training, education, and support to improve quality of life and physical conditioning.
  evidence:
  - reference: PMID:29526182
    reference_title: "Pulmonary Rehabilitation and Exercise Training in Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: PR is an effective and cost-effective therapeutic intervention that improves physical performance ability, shortness of breath, and the quality of life in patients with COPD.
    explanation: The reference indicates that pulmonary rehabilitation (PR) improves physical performance, shortness of breath, and quality of life in COPD patients, aligning with the statement's description of treatments including exercise training, education, and support.
  - reference: PMID:34338012
    reference_title: "Management of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Exercise improves the physiological and psychological condition of people with chronic obstructive pulmonary disease and should be encouraged, with referral to a pulmonary rehabilitation service if available.
    explanation: This reference supports the statement's claim by emphasizing the importance of exercise and recommending pulmonary rehabilitation to improve the quality of life and physical conditioning in COPD patients.
  - reference: PMID:34955635
    reference_title: "Self-Efficacy Intervention Programs in Patients with Chronic Obstructive Pulmonary Disease: Narrative Review."
    supports: SUPPORT
    snippet: The combination of drug therapy with non-drug therapy such as pulmonary rehabilitation training has demonstrated a great potential in reducing the occurrence of complications and delaying the progression of COPD.
    explanation: This reference supports the statement by highlighting the benefits of pulmonary rehabilitation training, specifically its potential to improve quality of life and physical conditioning in COPD patients.
  - reference: PMID:24874124
    reference_title: "The systemic nature of chronic lung disease."
    supports: SUPPORT
    snippet: Pulmonary rehabilitation targets the systemic manifestations of COPD, the causes of which include inactivity, systemic inflammation, hypoxia and corticosteroid treatment.
    explanation: This reference supports the statement by indicating that pulmonary rehabilitation addresses systemic issues in COPD and implies improvement in quality of life and physical conditioning.
  - reference: PMID:24507849
    reference_title: "Pulmonary rehabilitation."
    supports: SUPPORT
    snippet: The main objective of pulmonary rehabilitation is to restore muscle function and exercise tolerance, reverse other nonrespiratory consequences of the disease, and help patients to self-manage chronic obstructive pulmonary disease and its exacerbations and symptoms.
    explanation: This reference supports the statement by detailing the benefits of pulmonary rehabilitation, including exercise training, education, and support, to improve quality of life and physical conditioning.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Lung Volume Reduction Surgery
  description: Surgical removal of damaged lung tissue for severe emphysema.
  evidence:
  - reference: PMID:22189668
    reference_title: "Lung volume reduction for advanced emphysema: surgical and bronchoscopic approaches."
    supports: SUPPORT
    snippet: Surgical approaches include lung transplantation and lung volume reduction and the latter has been shown to improve exercise tolerance, quality of life, and survival in highly selected patients with advanced emphysema.
    explanation: The literature supports the use of lung volume reduction surgery as a treatment for severe emphysema in chronic obstructive pulmonary disease (COPD) patients.
  - reference: PMID:33926668
    reference_title: "Alpha(1)-antitrypsin Disease, Treatment and Role for Lung Volume Reduction Surgery."
    supports: SUPPORT
    snippet: As symptoms and lung function decline, treatment modalities, such as lung volume reduction surgery, have been used in individuals with chronic obstructive pulmonary disease and upper lobe predominant emphysema.
    explanation: The literature indicates that lung volume reduction surgery is a treatment used for severe emphysema, a condition associated with COPD.
  - reference: PMID:31145187
    reference_title: "Emerging Interventional Pulmonary Therapies for Chronic Obstructive Pulmonary Disease."
    supports: SUPPORT
    snippet: 'Mortality benefits to therapy have been demonstrated in only 2 therapeutic interventions to date: long-term use of daily supplemental oxygen and surgical lung volume reduction (LVRS) for upper-lobe-predominant disease in patients with a low baseline exercise capacity.'
    explanation: The statement is supported as the literature suggests that lung volume reduction surgery is an established treatment for upper-lobe-predominant, severe emphysema in COPD patients.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Lung Transplantation
  description: Considered in end-stage COPD with severe impairment.
  evidence:
  - reference: PMID:17240617
    reference_title: "Transplantation in chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Lung transplantation is a surgical option for patients who fail optimization of medical treatment for the severe symptoms that result from COPD.
    explanation: This reference states that lung transplantation is a considered treatment option for patients with severe symptoms resulting from COPD.
  - reference: PMID:31375190
    reference_title: "Palliative Care Approach to Chronic Diseases: End Stages of Heart Failure, Chronic Obstructive Pulmonary Disease, Liver Failure, and Renal Failure."
    supports: SUPPORT
    snippet: End-stage congestive heart failure, chronic obstructive pulmonary disease...palliative principles can guide decision making and symptom management in these disease states.
    explanation: The reference focuses on end-stage COPD and mentions lung transplantation as a consideration in managing the conditions of patients.
  - reference: PMID:36050206
    reference_title: "The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-ninth adult lung transplantation report-2022; focus on lung transplant recipients with chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: The International Thoracic Organ Transplant Registry...focus on lung transplant recipients with chronic obstructive pulmonary disease.
    explanation: This source concentrates on lung transplantation for patients with COPD, in line with the statement's context of it being a treatment for end-stage COPD.
  - reference: PMID:23248802
    reference_title: "A brief review of chronic obstructive pulmonary disease."
    supports: SUPPORT
    snippet: Chronic obstructive pulmonary disease...treated by lung transplantation.
    explanation: This abstract explicitly mentions the use of lung transplantation for individuals with very severe COPD.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
- name: Mucolytic Therapy
  description: N-acetylcysteine and other mucolytics reduce mucus viscosity and may improve mucociliary clearance.
  notes: Variable clinical impact across COPD phenotypes; targets MUC5AC/MUC5B expression and mucus rheology.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Macrolide Antibiotics
  description: Long-term macrolide therapy reduces exacerbation frequency but raises antimicrobial resistance concerns.
  notes: Used in chronic bronchitis phenotype; dual anti-inflammatory and antimicrobial effects.
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
- name: Biologic Therapies
  description: Precision biologics targeting Type 2 inflammation in eosinophilic COPD subsets.
  notes: Dupilumab (anti-IL-4/IL-13) shows benefit in eosinophilic COPD; anti-IL-33 and anti-TSLP under investigation.
  treatment_term:
    preferred_term: biologic therapy
    term:
      id: NCIT:C15262
      label: Immunotherapy
review_notes: COPD is characterized by progressive airflow obstruction that is not fully reversible. Key respiratory symptoms include dyspnea, chronic cough, sputum production, and wheezing. As the disease progresses, patients may develop signs of lung hyperinflation (barrel chest) and are at risk for respiratory failure. Systemic effects like fatigue and weight loss are also common, particularly in advanced disease.
discussions:
- discussion_id: gap_copd_sirt1_senescence_neutrophilic_translation
  prompt: >-
    Does restoring NAD+-dependent SIRT1 deacetylase activity causally reduce
    neutrophilic airway inflammation and alveolar epithelial senescence in COPD,
    and can SIRT1 activators overcome their pharmacokinetic limitations and be
    paired with biomarker-guided patient stratification to translate this
    protection into therapy?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Chronic Inflammation
  - pathophysiology#Cellular Senescence
  rationale: >-
    SIRT1 is reported to protect against COPD by inhibiting NF-kB and STAT3,
    activating Nrf2 and FOXO3, and suppressing TGF-beta/Smad, thereby reducing
    neutrophilic inflammation, mitigating alveolar epithelial senescence, and
    helping restore protease/antiprotease balance. These protective effects are
    mechanistically distinct from SIRT1's role in asthma, where it chiefly
    attenuates type 2 inflammation and mucus hypersecretion, so the disease
    context appears to determine which downstream program SIRT1 restrains. The
    COPD entry captures chronic neutrophilic inflammation and cellular senescence
    as separate nodes but does not resolve whether SIRT1 activity is causally
    required to limit each one, nor in which cell type (alveolar epithelium,
    neutrophil, macrophage) the protective signaling resides. Translation is
    further limited by the poor pharmacokinetics of current SIRT1 activators and
    by the absence of biomarkers to select responders. Resolving the
    cell-type-specific basis of these context-dependent effects and the
    pharmacokinetic and stratification barriers would convert SIRT1 from a
    broadly cytoprotective pathway into a stratified COPD therapeutic target.
  notes: "Seeded from PMID:42181267 — Emerging role of SIRT1 in asthma and COPD from molecular mechanisms to translational therapy"
disease_term:
  preferred_term: chronic obstructive pulmonary disease
  term:
    id: MONDO:0005002
    label: chronic obstructive pulmonary disease
classifications:
  harrisons_chapter:
  - classification_value: RESPIRATORY
references:
- reference: DOI:10.1136/thorax-2023-220455
  title: Lower airway microbiota in COPD and healthy controls
  findings: []
- reference: DOI:10.1164/rccm.202306-1060oc
  title: Accelerated Lung Function Decline and Mucus–Microbe Evolution in Chronic Obstructive Pulmonary Disease
  findings: []
- reference: DOI:10.1183/23120541.00177-2024
  title: What every clinician should know about inflammation in COPD
  findings: []
- reference: DOI:10.3389/fimmu.2024.1404615
  title: Inflammation mechanism and research progress of COPD
  findings: []
- reference: DOI:10.3390/ijms25147780
  title: Cellular and Molecular Biology of Mitochondria in Chronic Obstructive Pulmonary Disease
  findings: []
- reference: DOI:10.3390/ijms26052184
  title: 'Molecular Approaches to Treating Chronic Obstructive Pulmonary Disease: Current Perspectives and Future Directions'
  findings: []
📚

References & Deep Research

References

6
DOI:10.1136/thorax-2023-220455
Lower airway microbiota in COPD and healthy controls
No top-level findings curated for this source.
DOI:10.1164/rccm.202306-1060oc
Accelerated Lung Function Decline and Mucus–Microbe Evolution in Chronic Obstructive Pulmonary Disease
No top-level findings curated for this source.
DOI:10.1183/23120541.00177-2024
What every clinician should know about inflammation in COPD
No top-level findings curated for this source.
DOI:10.3389/fimmu.2024.1404615
Inflammation mechanism and research progress of COPD
No top-level findings curated for this source.
DOI:10.3390/ijms25147780
Cellular and Molecular Biology of Mitochondria in Chronic Obstructive Pulmonary Disease
No top-level findings curated for this source.
DOI:10.3390/ijms26052184
Molecular Approaches to Treating Chronic Obstructive Pulmonary Disease: Current Perspectives and Future Directions
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Chronic_Obstructive_Pulmonary_Disease
  • Category: Complex
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 109

Key Pathophysiology Nodes

  • Airflow Limitation
  • Chronic Inflammation
  • Airway Remodeling
  • Alveolar Destruction
  • Oxidative Stress and Mitochondrial Dysfunction
  • Mucus Hypersecretion
  • NLRP3 Inflammasome Activation
  • Cellular Senescence
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1136/thorax-2023-220455
  • DOI:10.1164/rccm.202306-1060oc
  • DOI:10.1183/23120541.00177-2024
  • DOI:10.3389/fimmu.2024.1404615
  • DOI:10.3390/ijms25147780
  • DOI:10.3390/ijms26052184
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 18 citations 2025-12-15T09:08:56.269301

Disease Pathophysiology Research Report

Target Disease - Disease Name: Chronic Obstructive Pulmonary Disease (COPD) - MONDO ID: MONDO:0005002 - Category: Complex

Pathophysiology description (current understanding, 2023–2024) COPD is a heterogeneous chronic inflammatory lung disease characterized by persistent airflow limitation arising from small airway disease (airway wall thickening, fibrosis, mucus plugging) and parenchymal destruction (emphysema). A pathogenic triad—chronic inflammation, protease–antiprotease imbalance, and oxidative stress—interacts with cellular senescence, mitochondrial dysfunction, mucociliary failure, inflammasome activation, dysbiosis, and autoimmunity to drive progression from early small-airway pathology to emphysema and chronic bronchitis (mucus hypersecretion) phenotypes (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2). Oxidative stress and impaired mitochondrial quality control amplify inflammation and inflammasome signaling; senescent epithelial, fibroblast, and immune cells propagate a SASP cytokine milieu; excess neutrophil and macrophage proteases degrade elastin and extracellular matrix; airway epithelial remodeling increases MUC5AC/MUC5B and impairs mucociliary transport; and airway microbiome interactome disturbance (loss of antagonistic interactions) correlates with neutrophilic inflammation, symptoms, and exacerbation risk (li2024cellularandmolecular pages 11-12, xu2024inflammationmechanismand pages 7-8, vu2025molecularapproachesto pages 9-10).

Mechanistic axis Key molecules (HGNC symbols) Principal cells (CL terms) Subcellular / compartment Evidence highlights (1–2 sentences) Sources (DOI + year)
Chronic inflammation & endotypes TNF, IL1B, IL6, CXCL8, IL17A, IL5 Neutrophil (CL), Alveolar macrophage (CL), CD8+ T cell (CL), Eosinophil (CL) Cytokine signaling / NF-κB (cytosol → nucleus) Persistent mixed neutrophilic/eosinophilic airway inflammation defines heterogeneous endotypes; blood/sputum eosinophils predict ICS response and guide biologics (xu2024inflammationmechanismand pages 7-8, wechsler2024whateveryclinician pages 11-12). 10.3389/fimmu.2024.1404615 (2024); 10.1183/23120541.00177-2024 (2024)
Protease–antiprotease imbalance ELANE (neutrophil elastase), MMP12, SERPINA1 (A1AT) Neutrophil (CL), Macrophage (CL) Extracellular matrix / elastin degradation Excess neutrophil proteases and MMPs degrade ECM and elastin promoting emphysema; A1AT deficiency exacerbates proteolytic damage (wechsler2024whateveryclinician pages 11-12, xu2024inflammationmechanismand pages 7-8). 10.1183/23120541.00177-2024 (2024); 10.3389/fimmu.2024.1404615 (2024)
Oxidative stress & mitochondrial dysfunction NFE2L2 (Nrf2), SOD2, SIRT1, NOX family Airway epithelial cells (CL), Alveolar macrophage (CL) Mitochondria, ROS, impaired mitophagy Cigarette smoke–driven mitochondrial ROS and defective mitophagy amplify inflammation and may impair steroid responsiveness; mitochondria-targeted antioxidants are proposed (li2024cellularandmolecular pages 11-12, xu2024inflammationmechanismand pages 7-8). 10.3390/ijms25147780 (2024); 10.3389/fimmu.2024.1404615 (2024)
Cellular senescence & SASP CDKN2A (p16), CDKN1A (p21), IL6, MMPs Epithelial cells (CL), Fibroblasts (CL), Macrophages (CL) Nuclear DNA damage, SASP secretion Senescent lung cells secrete SASP (eg, IL‑6, CXCL8, MMPs) driving chronic inflammation and remodeling; senolytic/senomorphic strategies show preclinical promise (wechsler2024whateveryclinician pages 11-12, xu2024inflammationmechanismand pages 7-8). 10.1183/23120541.00177-2024 (2024); 10.3389/fimmu.2024.1404615 (2024)
Mucus hypersecretion / mucociliary dysfunction MUC5AC, MUC5B, EGFR Goblet cell (CL), Club cell (CL), Ciliated cell (CL) Secreted mucin polymers / apical mucus layer MUC5AC/MUC5B overexpression and goblet cell hyperplasia increase mucus viscosity and impair clearance; mucolytics (eg, NAC) and mucin-targeted agents are under investigation (xu2024inflammationmechanismand pages 7-8, vu2025molecularapproachesto pages 9-10). 10.3389/fimmu.2024.1404615 (2024); 10.3390/ijms26052184 (2025)
Small airway remodeling & emphysema MMP9, MMP12, TGFB1 (TGF‑β1), COL1A1 Small airway epithelial cells (CL), Fibroblasts (CL), Smooth muscle cells (CL) ECM deposition, elastin degradation Loss and stenosis of terminal bronchioles with peribronchiolar fibrosis and emphysematous alveolar destruction drive irreversible airflow limitation (wechsler2024whateveryclinician pages 11-12, xu2024inflammationmechanismand pages 7-8). 10.1183/23120541.00177-2024 (2024); 10.3389/fimmu.2024.1404615 (2024)
Inflammasome / pyroptosis (NLRP3) NLRP3, CASP1, IL1B, IL18 Macrophage (CL), Epithelial cell (CL) Cytosolic inflammasome assembly → caspase‑1 → GSDMD pores Mitochondrial ROS and particulate exposures activate NLRP3 → caspase‑1 → IL‑1β/IL‑18 release and pyroptosis, linking exposures to tissue damage (li2024cellularandmolecular pages 11-12, vu2025molecularapproachesto pages 9-10). 10.3390/ijms25147780 (2024); 10.3390/ijms26052184 (2025)
Autoimmunity & B cell follicles TNFSF13B (BAFF), AICDA, autoantibodies B cell (CL), T follicular helper cell (CL), Ectopic lymphoid structures Local germinal center–like activity in lung Ectopic B‑cell follicles and autoantibodies to modified self-proteins may perpetuate inflammation in subsets of COPD; autoimmune links to comorbidity noted (xu2024inflammationmechanismand pages 7-8). 10.3389/fimmu.2024.1404615 (2024)
Microbiome dysbiosis / interactome — (taxa-level: Haemophilus, Moraxella, Pseudomonas) Airway epithelial cells (CL), Macrophages (CL) Mucus niche / biofilm communities Loss of antagonistic bacterial interactions and reduced alpha‑diversity associate with worse symptoms, neutrophilic inflammation and exacerbation risk (microbiome–mucus coupling) (vu2025molecularapproachesto pages 9-10, xu2024inflammationmechanismand pages 7-8). 10.3390/ijms26052184 (2025); 10.3389/fimmu.2024.1404615 (2024)
Environmental exposures (PM2.5) synergy TLR4, NLRP3, RELA (NF‑κB p65) Epithelial cells (CL), Macrophages (CL), Neutrophils (CL) Particle uptake, endosomal/mitochondrial ROS PM2.5 worsens smoke-induced injury by amplifying ROS/NLRP3/caspase‑1 signaling and correlates with worse symptoms/QoL in smokers with COPD (vu2025molecularapproachesto pages 9-10, li2024cellularandmolecular pages 11-12). 10.3390/ijms26052184 (2025); 10.3390/ijms25147780 (2024)
Therapeutics / applications (selected) IL4R (dupilumab), NFE2L2 (Nrf2 activators), GCLC/GPX (glutathione pathways), PDE4 (PDE4 inhibitors) Varies by target (immune cells, epithelial targets) Mechanism-dependent (eg, receptor blockade, antioxidant induction) Precision biologics (eg, anti‑IL‑4/IL‑13 dupilumab) show benefit in eosinophilic COPD; antioxidants (NAC, Nrf2 agonists), PDE inhibitors, inflammasome inhibitors and senolytics are active translational pathways (~100 molecular/biologic COPD trials ongoing) (vu2025molecularapproachesto pages 12-13, vu2025molecularapproachesto pages 9-10). 10.3390/ijms26052184 (2025); 10.3389/fimmu.2024.1404615 (2024)

Table: Compact, citation‑ready summary of major mechanistic axes in COPD (2023–2025), listing key molecules, principal cell types, subcellular locations, short evidence statements, and source DOIs for rapid integration into a knowledge base.

1) Core pathophysiological mechanisms - Chronic inflammation and endotypes: COPD airway inflammation involves neutrophils, macrophages, CD8+ T cells, and in subsets eosinophils/Type 2 biology. Eosinophilic COPD predicts inhaled corticosteroid responsiveness, whereas neutrophilic endotypes often show steroid resistance and benefit from PDE4 inhibition (roflumilast) (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2). Systemic inflammation (CRP, IL-6, TNF-α, fibrinogen) associates with comorbidities and outcomes (xu2024inflammationmechanismand pages 7-8). - Protease–antiprotease imbalance: Neutrophil elastase (ELANE) and macrophage MMP12, among other MMPs/serine proteases, overwhelm antiproteases (notably α1-antitrypsin, SERPINA1) leading to elastin destruction and emphysema; α1-antitrypsin deficiency exemplifies causal imbalance (wechsler2024whateveryclinician pages 2-3). - Oxidative stress and mitochondrial dysfunction: Cigarette smoke and pollutants trigger mitochondrial ROS, altered dynamics (fragmentation), impaired mitophagy and bioenergetic defects in airway epithelium and macrophages. Reduced Nrf2/FOXO3a activity diminishes antioxidant defenses; mitochondrial ROS activates NLRP3 and sustains inflammaging (li2024cellularandmolecular pages 11-12, xu2024inflammationmechanismand pages 7-8). - Cellular senescence: Senescent epithelial and stromal/immune cells exhibit SASP (IL‑6, CXCL8, MMPs), promoting remodeling and persistent inflammation; senescence is a hallmark of accelerated lung ageing in COPD (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 7-8). - Mucus hypersecretion and mucociliary dysfunction: Upregulation of MUC5AC/MUC5B, goblet cell hyperplasia and club-to-goblet transdifferentiation impair clearance and promote mucus plugging; mucolytics and mucoregulators (eg, NAC) target this axis (xu2024inflammationmechanismand pages 1-2, vu2025molecularapproachesto pages 9-10). - Small-airway remodeling and emphysema: Early loss and stenosis of terminal bronchioles with peribronchiolar fibrosis precede emphysema; many patients exhibit mixed pathology (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2). - Inflammasome and pyroptosis: Mitochondrial ROS and particulate exposure activate NLRP3→caspase‑1→IL‑1β/IL‑18, promoting pyroptosis and airway inflammation; PM2.5 synergizes with cigarette smoke to aggravate injury via NLRP3/caspase‑1 (li2024cellularandmolecular pages 11-12, vu2025molecularapproachesto pages 9-10). - Autoimmunity: Ectopic B-cell follicles (tertiary lymphoid structures) and autoantibodies to oxidatively modified self-antigens are reported, potentially sustaining inflammation in severe COPD (xu2024inflammationmechanismand pages 7-8). - Microbiome dysbiosis and interactome disturbance: COPD shows reduced evenness and altered composition in lower airways; during exacerbations antagonistic bacterial interactions diminish and recover post-treatment, linking network disturbance more strongly than diversity to symptoms, lung function and neutrophilic inflammation (xu2024inflammationmechanismand pages 7-8, vu2025molecularapproachesto pages 9-10).

2) Key molecular players - Genes/proteins: ELANE (neutrophil elastase), MMP12/MMP9, SERPINA1 (α1-antitrypsin), NLRP3, CASP1, IL1B, IL18, TNF, TNFRSF1A (TNFR1), RELA (NF‑κB p65), IL17A, TLR4, EGFR, MUC5AC/MUC5B, HDAC5/6, NFE2L2 (Nrf2), SIRT1, PPARG (wechsler2024whateveryclinician pages 2-3, li2024cellularandmolecular pages 11-12, xu2024inflammationmechanismand pages 7-8). - Chemical entities: Oxidants/ROS; mucolytic N‑acetylcysteine; PDE4 inhibitor roflumilast; antioxidants and Nrf2 activators (eg, sulforaphane, CDDO-class) in development; macrolides for exacerbation prevention; biologics targeting Type 2 pathways (eg, dupilumab, anti‑IL‑33/TSLP under study) (vu2025molecularapproachesto pages 9-10, vu2025molecularapproachesto pages 12-13). - Cell types: Airway epithelial subsets (basal, ciliated, club, goblet), alveolar type 2 cells; alveolar/interstitial macrophages; neutrophils; CD8+ T cells; B cells within tertiary lymphoid structures; fibroblasts and airway smooth muscle; endothelial cells (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2). - Anatomical locations: Small conducting airways (terminal/respiratory bronchioles), bronchi, alveoli (acini), airway surface liquid/mucus layer; lung interstitium and extracellular matrix (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2).

3) Biological processes (GO) disrupted - Inflammatory response; neutrophil chemotaxis/degranulation; proteolysis; extracellular matrix organization; response to oxidative stress; mitochondrial organization and mitophagy; cellular senescence; mucin biosynthetic process; cilium movement/mucociliary clearance; NLRP3 inflammasome complex assembly; NF‑κB signaling; TLR signaling; IL‑17 signaling (wechsler2024whateveryclinician pages 2-3, li2024cellularandmolecular pages 11-12, xu2024inflammationmechanismand pages 7-8).

4) Cellular components (GO) implicated - Mitochondrion (cristae, outer membrane); inflammasome complex (cytosol); nucleus (NF‑κB translocation); extracellular matrix (elastin fibers); apical secretory granules and mucus gel; cilia/axoneme; plasma membrane receptors (EGFR, TLR4, TNFR1) (li2024cellularandmolecular pages 11-12, wechsler2024whateveryclinician pages 2-3).

5) Disease progression and stages - Sequence: Repeated noxious exposures (smoke, biomass, pollution) → oxidative stress and epithelial injury → small-airway inflammation and peribronchiolar fibrosis with loss/stenosis of terminal bronchioles → mucus hypersecretion and mucostasis → parenchymal destruction (emphysema) and persistent airflow limitation. Distinct phenotypes: chronic bronchitis (productive cough with MUC5AC/MUC5B upregulation), emphysema-dominant, and mixed; endotypes span eosinophilic (Type 2-high) and neutrophilic (Type 2-low) inflammation with different therapeutic responses (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2).

6) Phenotypic manifestations (link to mechanisms) - Clinical phenotypes include dyspnea, chronic cough/sputum, recurrent exacerbations, and airflow obstruction. Eosinophilic COPD is associated with steroid responsiveness; neutrophilic COPD correlates with protease burden, NETs, and mucus plugging; mucus–microbiome evolution over time associates with accelerated FEV1 decline and emergence of pathogenic genera (Haemophilus, Moraxella, Pseudomonas) (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 7-8).

7) Microbiome dynamics (stability vs exacerbation) - Lower airway microbiota in COPD exhibits reduced evenness versus controls and shows smoking-related differences; exacerbations are characterized by reduced antagonistic interactions in bacterial networks rather than simple diversity loss, which recover after therapy. Longitudinal cohorts show evolving mucus–microbiome profiles associating with symptom progression and lung function decline (xu2024inflammationmechanismand pages 7-8, vu2025molecularapproachesto pages 9-10).

Current applications and real-world implementations - Biologics/endotype targeting: Dupilumab (IL‑4Rα blockade, IL‑4/IL‑13 axis) has shown benefit in eosinophilic COPD; alarmin-targeting biologics (anti‑IL‑33/TSLP) are under active study. Clinicians increasingly phenotype by blood eosinophils and exacerbation history to guide ICS or biologics (vu2025molecularapproachesto pages 12-13, wechsler2024whateveryclinician pages 2-3). - Anti-inflammatory small molecules: PDE4 inhibition (roflumilast) benefits chronic bronchitis/neutrophilic phenotypes; long-term macrolides reduce exacerbations but raise resistance concerns (vu2025molecularapproachesto pages 12-13, xu2024inflammationmechanismand pages 7-8). - Mucolytics/mucoregulators: N‑acetylcysteine acts as mucolytic and mucoregulator and is widely used; trials and reviews support effects on mucin expression/viscosity with variable clinical impact across phenotypes (vu2025molecularapproachesto pages 9-10). - Antioxidant/mitochondrial strategies: Nrf2 agonists, glutathione peroxidase mimetics (ebselen), and mitochondria-targeted antioxidants are under investigation to address oxidative stress and mitochondrial quality control defects (vu2025molecularapproachesto pages 9-10, li2024cellularandmolecular pages 11-12). - Inflammasome targeting and pollution mitigation: Preclinical/clinical translational work links PM2.5 to NLRP3 activation; blocking NLRP3/caspase‑1 signaling and environmental exposure reduction represent emerging strategies (vu2025molecularapproachesto pages 9-10).

Statistics and data points from recent studies - Microbiome evenness and diversity: In a protected BAL case–control study (n=97 COPD, n=97 controls), alpha diversity was significantly lower in COPD (Pielou evenness 0.76 vs 0.80, p=0.004; Shannon 3.98 vs 4.34, p=0.01) (Thorax 2024; doi:10.1136/thorax-2023-220455) (xu2024inflammationmechanismand pages 7-8). - Network interactome in exacerbations: Across 1,742 sputum microbiomes, COPD showed reproducibly reduced antagonistic bacterial interactions at stability and further during exacerbation, with recovery post-treatment; loss of antagonistic interactions associated with worse dyspnea, lower lung function, neutrophilia, and higher exacerbation risk (Respiratory Research 2024; doi reported in source) (vu2025molecularapproachesto pages 9-10). - Mucus–microbiome and lung function decline: A longitudinal cohort contrasting accelerated FEV1 decline (~156 ml/year) versus non-decline found increased mucin concentrations (MUC5AC/MUC5B) and emergence of pathogens (e.g., Pseudomonas, Haemophilus) in the accelerated group (AJRCCM 2024; doi:10.1164/rccm.202306-1060OC) (vu2025molecularapproachesto pages 9-10).

Gene/protein annotations with ontology terms - HGNC: ELANE; MMP12; SERPINA1; NLRP3; CASP1; IL1B; IL18; TNF; TNFRSF1A; RELA; IL17A; TLR4; EGFR; MUC5AC; MUC5B; HDAC5; HDAC6; NFE2L2; SIRT1; PPARG (wechsler2024whateveryclinician pages 2-3, li2024cellularandmolecular pages 11-12, xu2024inflammationmechanismand pages 7-8). - GO Biological Process (selected): inflammatory response; neutrophil degranulation; extracellular matrix organization; response to oxidative stress; regulation of mitophagy; cellular senescence; mucin biosynthetic process; cilium movement; inflammasome complex assembly; NF‑κB signaling (wechsler2024whateveryclinician pages 2-3, li2024cellularandmolecular pages 11-12). - GO Cellular Component (selected): mitochondrion; inflammasome complex; extracellular region (mucus); cilium; extracellular matrix (elastin fiber) (li2024cellularandmolecular pages 11-12, wechsler2024whateveryclinician pages 2-3). - Cell types (CL): airway epithelial cell (basal, ciliated, club, goblet); alveolar macrophage; neutrophil; CD8+ T cell; B cell; fibroblast; airway smooth muscle cell; endothelial cell (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2). - Anatomical locations (UBERON): small airways (terminal/respiratory bronchioles); bronchi; alveolus; airway surface liquid; pulmonary interstitium (wechsler2024whateveryclinician pages 2-3, xu2024inflammationmechanismand pages 1-2). - Chemical entities (ChEBI): reactive oxygen species; N‑acetylcysteine; macrolide antibiotics; phosphodiesterase inhibitors (roflumilast); electrophilic Nrf2 activators (vu2025molecularapproachesto pages 9-10).

Expert opinions and analysis - 2024 ERS Open Research review emphasizes heterogeneity of inflammation, centrality of small-airway disease, and the pathogenic triad framework, urging endotype-driven precision therapy and vigilance for mucus pathology and remodeling (wechsler2024whateveryclinician pages 2-3). 2024 Frontiers in Immunology review underscores mitochondrial dysfunction and immunosenescence, advocating mitochondria-targeted antioxidant strategies and biomarker-guided phenotyping (xu2024inflammationmechanismand pages 7-8). Together, these authoritative sources converge on multi-axis pathobiology and precision approaches.

Citations (URLs and dates) - Wechsler ME, Wells JM. What every clinician should know about inflammation in COPD. ERJ Open Res. 2024 May 20. doi:10.1183/23120541.00177-2024. https://doi.org/10.1183/23120541.00177-2024 (wechsler2024whateveryclinician pages 2-3). - Xu J, Zeng Q, Li S, et al. Inflammation mechanism and research progress of COPD. Front Immunol. 2024 Aug 2. doi:10.3389/fimmu.2024.1404615. https://doi.org/10.3389/fimmu.2024.1404615 (xu2024inflammationmechanismand pages 7-8, xu2024inflammationmechanismand pages 1-2). - Li C‑L, Liu S‑F. Cellular and molecular biology of mitochondria in COPD. Int J Mol Sci. 2024 Jul 18. doi:10.3390/ijms25147780. https://doi.org/10.3390/ijms25147780 (li2024cellularandmolecular pages 11-12). - Meldrum OW, Donaldson GC, et al. Accelerated Lung Function Decline and Mucus–Microbe Evolution in COPD. Am J Respir Crit Care Med. 2024 Aug 1;210(3):298–310. doi:10.1164/rccm.202306-1060OC. https://doi.org/10.1164/rccm.202306-1060OC (vu2025molecularapproachesto pages 9-10). - Tangedal S, et al. Lower airway microbiota in COPD and healthy controls. Thorax. 2024 Feb;79(3):219–226. doi:10.1136/thorax-2023-220455. https://doi.org/10.1136/thorax-2023-220455 (xu2024inflammationmechanismand pages 7-8). - Vu S‑P, Veit K, Sadikot RT. Molecular approaches to treating COPD. Int J Mol Sci. 2025 Feb. doi:10.3390/ijms26052184. https://doi.org/10.3390/ijms26052184 (vu2025molecularapproachesto pages 12-13, vu2025molecularapproachesto pages 9-10, vu2025molecularapproachesto pages 13-14).

Notes and limitations - While mitochondria- and inflammasome‑targeted strategies are promising, large RCT data remain limited as of 2023–2024. Microbiome network analyses provide mechanistic associations but interventional trials targeting interactomes are early-stage. Continued single‑cell and spatial profiling will refine cell‑type–specific mechanisms.

References

  1. (wechsler2024whateveryclinician pages 2-3): Michael E. Wechsler and J. Michael Wells. What every clinician should know about inflammation in copd. ERJ Open Research, 10:00177-2024, May 2024. URL: https://doi.org/10.1183/23120541.00177-2024, doi:10.1183/23120541.00177-2024. This article has 17 citations and is from a peer-reviewed journal.

  2. (xu2024inflammationmechanismand pages 1-2): Jiao Xu, Qingyue Zeng, Shuangqing Li, Qiaoli Su, and Hong Fan. Inflammation mechanism and research progress of copd. Frontiers in Immunology, Aug 2024. URL: https://doi.org/10.3389/fimmu.2024.1404615, doi:10.3389/fimmu.2024.1404615. This article has 113 citations and is from a peer-reviewed journal.

  3. (li2024cellularandmolecular pages 11-12): Chin-Ling Li and Shih-Feng Liu. Cellular and molecular biology of mitochondria in chronic obstructive pulmonary disease. International Journal of Molecular Sciences, 25:7780, Jul 2024. URL: https://doi.org/10.3390/ijms25147780, doi:10.3390/ijms25147780. This article has 5 citations and is from a poor quality or predatory journal.

  4. (xu2024inflammationmechanismand pages 7-8): Jiao Xu, Qingyue Zeng, Shuangqing Li, Qiaoli Su, and Hong Fan. Inflammation mechanism and research progress of copd. Frontiers in Immunology, Aug 2024. URL: https://doi.org/10.3389/fimmu.2024.1404615, doi:10.3389/fimmu.2024.1404615. This article has 113 citations and is from a peer-reviewed journal.

  5. (vu2025molecularapproachesto pages 9-10): Sheryl-Phuc Vu, Kaleb Veit, and Ruxana T. Sadikot. Molecular approaches to treating chronic obstructive pulmonary disease: current perspectives and future directions. International Journal of Molecular Sciences, 26:2184, Feb 2025. URL: https://doi.org/10.3390/ijms26052184, doi:10.3390/ijms26052184. This article has 3 citations and is from a poor quality or predatory journal.

  6. (wechsler2024whateveryclinician pages 11-12): Michael E. Wechsler and J. Michael Wells. What every clinician should know about inflammation in copd. ERJ Open Research, 10:00177-2024, May 2024. URL: https://doi.org/10.1183/23120541.00177-2024, doi:10.1183/23120541.00177-2024. This article has 17 citations and is from a peer-reviewed journal.

  7. (vu2025molecularapproachesto pages 12-13): Sheryl-Phuc Vu, Kaleb Veit, and Ruxana T. Sadikot. Molecular approaches to treating chronic obstructive pulmonary disease: current perspectives and future directions. International Journal of Molecular Sciences, 26:2184, Feb 2025. URL: https://doi.org/10.3390/ijms26052184, doi:10.3390/ijms26052184. This article has 3 citations and is from a poor quality or predatory journal.

  8. (vu2025molecularapproachesto pages 13-14): Sheryl-Phuc Vu, Kaleb Veit, and Ruxana T. Sadikot. Molecular approaches to treating chronic obstructive pulmonary disease: current perspectives and future directions. International Journal of Molecular Sciences, 26:2184, Feb 2025. URL: https://doi.org/10.3390/ijms26052184, doi:10.3390/ijms26052184. This article has 3 citations and is from a poor quality or predatory journal.